



CHAPTER

4

COMMON REPRODUCTIVE ISSUES

KEY TERMS

abortion	diaphragm	menopause
abstinence	dysfunctional uterine bleeding (DUB)	oral contraceptives
amenorrhea	dysmenorrhea	premenstrual syndrome (PMS)
basal body temperature (BBT)	emergency contraception (EC)	Standard Days Method (SDM)
cervical cap	endometriosis	sterilization
cervical mucus ovulation method	fertility awareness	symptothermal method
coitus interruptus	implant	transdermal patch
condoms	infertility	tubal ligation
contraception	lactational amenorrhea method (LAM)	vaginal ring
contraceptive sponge	Lunelle injection	vasectomy
Depo-Provera		

LEARNING OBJECTIVES

Upon completion of the chapter the learner will be able to:

1. Define the key terms used in this chapter.
2. Examine common reproductive concerns in terms of symptoms, diagnostic tests, and appropriate interventions.
3. Identify risk factors and outline appropriate client education needed in common reproductive disorders.
4. Compare and contrast the various contraceptive methods available and their overall effectiveness.
5. Explain the physiologic and psychological aspects of menopause.
6. Delineate the nursing management needed for women experiencing common reproductive disorders.

zzy, a 27-year-old, presents to her health care provider complaining of progressive severe pelvic pain associated with her monthly periods. She has to take off work and “dope myself up” with pills to endure the pain. In addition, she has been trying to conceive for over a year without any luck.

Wow

When women bare their souls to us, we must respond without judgment.

Good health throughout the life cycle begins with the individual. Women today can expect to live well into their 80s and need to be proactive in maintaining their own quality of life. Women need to take steps to reduce their risk of disease and need to become active partners with their health care professional to identify problems early, when treatment may be most successful (Teaching Guidelines 4.1). Nurses can assist women in maintaining their quality of life by helping them to become more attuned to their body and its clues and can use the assessment period as an opportunity for teaching and counseling.

Common reproductive issues addressed in this chapter that nurses might encounter in caring for women include menstrual disorders, infertility, contraception, abortion, and menopause.

Menstrual Disorders

Many women sail through their monthly menstrual cycles with little or no concern. With few symptoms to worry about, their menses are like clockwork, starting and stopping at nearly the same time every month. For others, the menstrual cycle causes physical and emotional symptoms that initiate visits to their health care provider for consultation. The following menstruation-related conditions will be discussed in this chapter: amenorrhea, dysmenorrhea, dysfunctional uterine bleeding (DUB), premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and endometriosis. To gain an understanding of menstrual disorders, it is important to know the terms used in describing them (Box 4.1).

TEACHING GUIDELINES 4.1

Tips for Being an Active Partner in Managing Your Health

- Become an informed consumer. Read, ask, and search.
- Know your family history and know factors that put you at high risk.
- Maintain a healthy lifestyle and let moderation be your guide.
- Schedule regular medical checkups and screenings for early detection.
- Ask your health care professional for a full explanation of any treatment.
- Seek a second medical opinion if you feel you need more information.
- Know when to seek medical care by being aware of disease symptoms.

BOX 4.1 Menstrual Disorder Vocabulary

- Meno = menstrual-related
- Metro = time
- Oligo = few
- A = without, none or lack of
- Rhagia = excess or abnormal
- Dys = not or pain
- Rhea = flow

AMENORRHEA

Amenorrhea is the absence of menses during the reproductive years. Amenorrhea is normal in prepubertal, pregnant, and postmenopausal females. The two categories of amenorrhea are primary and secondary amenorrhea. Primary amenorrhea is defined as either:

1. Absence of menses by age 14, with absence of growth and development of secondary sexual characteristics, or
2. Absence of menses by age 16, with normal development of secondary sexual characteristics (Bielak & Harris, 2006)

Ninety-eight percent of American girls menstruate by age 16 (Krantz, 2007a, 2007b). Secondary amenorrhea is the absence of menses for three cycles or 6 months in women who have previously menstruated regularly.

Etiology

There are multiple causes of primary amenorrhea:

- Extreme weight gain or loss
- Congenital abnormalities of the reproductive system
- Stress from a major life event
- Excessive exercise
- Eating disorders (anorexia nervosa or bulimia)
- Cushing's disease
- Polycystic ovary syndrome
- Hypothyroidism
- Turner syndrome
- Imperforate hymen
- Chronic illness
- Pregnancy
- Cystic fibrosis
- Congenital heart disease (cyanotic)
- Ovarian or adrenal tumors (Master-Hunter & Heiman, 2006)

Causes of secondary amenorrhea might include:

- Pregnancy
- Breastfeeding

- Emotional stress
- Pituitary, ovarian, or adrenal tumors
- Depression
- Hyperthyroid or hypothyroid conditions
- Malnutrition
- Hyperprolactinemia
- Rapid weight gain or loss
- Chemotherapy or radiation therapy to the pelvic area
- Vigorous exercise, such as long-distance running
- Kidney failure
- Colitis
- Use of tranquilizers or antidepressants
- Postpartum pituitary necrosis (Sheehan syndrome)
- Early menopause (Bielak & Harris, 2006)

Therapeutic Management

Therapeutic intervention depends on the cause of the amenorrhea. The treatment of primary amenorrhea involves the correction of any underlying disorders and estrogen replacement therapy to stimulate the development of secondary sexual characteristics. If a pituitary tumor is the cause, it might be treated with drug therapy, surgical resection, or radiation therapy. Surgery might be needed to correct any structural abnormalities of the genital tract. Therapeutic interventions for secondary amenorrhea may include:

- Cyclic progesterone, when the cause is anovulation, or oral contraceptives
- Bromocriptine to treat hyperprolactinemia
- Nutritional counseling to address anorexia, bulimia, or obesity
- Gonadotropin-releasing hormone (GnRH), when the cause is hypothalamic failure
- Thyroid hormone replacement, when the cause is hypothyroidism (Schuiling & Likis, 2006)

Nursing Assessment

Nursing assessment for the young girl or woman experiencing amenorrhea includes a thorough health history and physical examination and several laboratory and diagnostic tests.

Health History and Physical Examination

A thorough history and physical examination is needed to determine the etiology. The history should include questions about the women's menstrual history; past illnesses; hospitalizations and surgeries; obstetric history; use of prescription and over-the-counter drugs; recent or past lifestyle changes; and history of present illness, with an assessment of any bodily changes.

The physical examination should begin with an overall assessment of the woman's nutritional status and general health. A sensitive and gentle approach to the pelvic examination is critical in young women. Height and weight should be taken, along with vital signs. Hypothermia,

bradycardia, hypotension, and reduced subcutaneous fat may be observed in women with anorexia nervosa. Facial hair and acne might be evidence of androgen excess secondary to a tumor. The presence or absence of axillary and pubic hair may indicate adrenal and ovarian hyposecretion or delayed puberty. A general physical examination may uncover unexpected findings that are indirectly related to amenorrhea. For example, hepatosplenomegaly, which may suggest a chronic systemic disease or an enlarged thyroid gland, might point to a thyroid disorder as well as a reason for amenorrhea (Nelson & Bakalov, 2006).

Laboratory and Diagnostic Tests

Common laboratory tests that might be ordered to determine the cause of amenorrhea include:

- Karyotype (might be positive for Turner syndrome)
- Ultrasound to detect ovarian cysts
- Pregnancy test to rule out pregnancy
- Thyroid function studies to determine thyroid disorder
- Prolactin level (an elevated level might indicate a pituitary tumor)
- Follicle-stimulating hormone (FSH) level (an elevated level might indicate ovarian failure)
- Luteinizing hormone (LH) level (an elevated level might indicate gonadal dysfunction)
- 17-ketosteroids (an elevated level might indicate an adrenal tumor)
- Laparoscopy to detect polycystic ovary syndrome
- CT scan of head if a pituitary tumor is suspected (Pagana & Pagana, 2007)

Nursing Management

Counseling and education are primary interventions and appropriate nursing roles. Address the diverse causes of amenorrhea, the relationship to sexual identity, possible infertility, and the possibility of a tumor or a life-threatening disease. In addition, inform the woman about the purpose of each diagnostic test, how it is performed, and when the results will be available to discuss with her. Sensitive listening, interviewing, and presenting treatment options are paramount to gain the woman's cooperation and understanding.

Nutritional counseling is also vital in managing this disorder, especially if the woman has findings suggestive of an eating disorder. Although not all causes can be addressed by making lifestyle changes, emphasize maintaining a healthy lifestyle (Teaching Guidelines 4.2).

► DYSMENORRHEA

Dysmenorrhea refers to painful menstruation. This condition has also been termed cyclic perimenstrual pain (CPPD) (Taylor, 2005). The term **dysmenorrhea** is derived from

TEACHING GUIDELINES 4.2

Tips for Maintaining a Healthy Lifestyle

- Balance energy expenditure with energy intake.
- Modify your diet to maintain ideal weight.
- Avoid excessive use of alcohol and mood-altering or sedative drugs.
- Avoid cigarette smoking.
- Identify areas of emotional stress and seek assistance to resolve them.
- Balance work, recreation, and rest.
- Maintain a positive outlook regarding the diagnosis and prognosis.
- Participate in ongoing care to monitor any medical conditions.
- Maintain bone density through:
 - Calcium intake (1,200 to 1,500 mg daily)
 - Weight-bearing exercise (30 minutes or more daily)
 - Hormone therapy

Source: Nelson & Bakalov, 2006.

the Greek words “dys,” meaning difficult, painful, or abnormal, and “rrhea,” meaning flow. It may affect more than half of menstruating women (Smith, 2006). Uterine contractions occur during all periods, but in some women these cramps can be frequent and very intense. Dysmenorrhea is categorized as primary or secondary.

Etiology

Primary dysmenorrhea is caused by increased prostaglandin production by the endometrium in an ovulatory cycle. This hormone causes contraction of the uterus, and levels tend to be higher in women with severe menstrual pain than women who experience mild or no menstrual pain. These levels are highest during the first 2 days of menses, when symptoms peak (Doty & Attaran, 2006). This results in increased rhythmic uterine contractions from vasoconstriction of the small vessels of the uterine wall. This condition usually begins within a few years of the onset of ovulatory cycles at menarche.

Secondary dysmenorrhea is painful menstruation due to pelvic or uterine pathology. It may be caused by endometriosis, adenomyosis, fibroids, pelvic infection, an intrauterine device, cervical stenosis, or congenital uterine or vaginal abnormalities. Adenomyosis involves the ingrowth of the endometrium into the uterine musculature. Endometriosis involves ectopic implantation of endometrial tissue in other parts of the pelvis. It occurs most commonly in the third or fourth decades of life and affects 10% of women of reproductive age (Hompe &

Mijatovic, 2007). Endometriosis is the most common cause of secondary dysmenorrhea and is associated with pain beyond menstruation, dyspareunia, and infertility (Speroff & Fritz, 2005). Treatment is directed toward removing the underlying pathology.

Think back to Izzy from the chapter opener. Is her pelvic pain complaint a common one with women?

Therapeutic Management

Therapeutic intervention is directed toward pain relief and building coping strategies that will promote a productive lifestyle. Treatment measures usually include treating infections if present; suppressing the endometrium if endometriosis is suspected by administering low-dose oral contraceptives; administering prostaglandin inhibitors to reduce the pain; administering Depo-Provera; and initiating lifestyle changes. Table 4.1 lists selected treatment options for dysmenorrhea.

Nursing Assessment

As with any gynecologic complaint, a thorough focused history and physical examination is needed to make the diagnosis of primary or secondary dysmenorrhea. In primary dysmenorrhea, the history usually reveals the typical cramping pain with menstruation, and the physical examination is completely normal. In secondary dysmenorrhea, the history discloses cramping pain starting after 25 years old with a pelvic abnormality, a history of infertility, heavy menstrual flow, irregular cycles, and little response to non-steroidal anti-inflammatory drugs (NSAIDs), oral contraceptives, or both (Harel, 2006).

Health History and Clinical Manifestations

Note past medical history, including any chronic illnesses and family history of gynecologic concerns. Determine medication and substance use, such as prescription medications, contraceptives, anabolic steroids, tobacco, and marijuana, cocaine, or other illegal drugs. A detailed sexual history is essential to assess for inflammation and scarring (adhesions) secondary to pelvic inflammatory disease (PID). Women with a previous history of PID, sexually transmitted infections (STIs), multiple sexual partners, or unprotected sex are at increased risk.

During the initial interview, the nurse might ask some of the following questions to assess the woman's history of dysmenorrhea:

- “At what age did you start your menstrual cycles?”
- “Have your cycles always been painful, or did the pain start recently?”
- “When in your cycle do you experience the pain?”
- “How would you describe the pain you feel?”

TABLE 4.1 TREATMENT OPTIONS FOR DYSMENORRHEA

Therapy Options	Dosage	Comments
Nonsteroidal anti-inflammatory agents (NSAIDs) Ibuprofen (Ibuprofen, Advil, Motrin) Naproxen (Anaprox, Naprelan, Naprosyn, Aleve)	400–800 mg TID 250–500 mg TID	Take with meals. Don't take with aspirin. Avoid alcohol. Watch for signs of GI bleeding. Same as above
Hormonal contraceptives Low-dose oral contraceptives Depo-medroxyprogesterone (DMPA), Depo-Provera	Taken daily (42/7 days; 63/7 or 84/7) 150 mg IM every 12 wks	Take active pills for an extended time to reduce number of monthly cycles (Archer, 2006). Within 9–12 months of DMPA therapy, 75% of women will be amenorrheic (Schuiling & Likis, 2006).
Lifestyle changes Daily exercise Limit salty foods Weight loss Smoking cessation Relaxation techniques		Gives sense of control over life

- “Are you sexually active?”
- “What impact does your cycle have on your physical and social activity?”
- “When was the first day of your last menstrual cycle?”
- “Was the flow of your last menstrual cycle a normal amount for you?”
- “Do your cycles tend to be heavy or last longer than 5 days?”
- “Are your cycles generally regular and predictable?”
- “What have you done to relieve your discomfort? Is it effective?”
- “Has there been a progression of symptom severity?”
- “Do you have any other symptoms?”

Assess for clinical manifestations of dysmenorrhea. Affected women experience sharp, intermittent spasms of pain, usually in the suprapubic area. Pain may radiate to the back of the legs or the lower back. Pain usually develops within hours of the start of menstruation and peaks as the flow becomes heaviest during the first day or two of the cycle (Edmundson & Erogul, 2006). Systemic symptoms of nausea, vomiting, diarrhea, fatigue, fever, headache, or dizziness are fairly common. Explore the history for physi-

cal symptoms of bloating, water retention, weight gain, headache, muscle aches, abdominal pain, food cravings, or breast tenderness.

Physical Examination

The physical examination performed by the health care provider centers on the bimanual pelvic examination. This examination is done during the nonmenstrual phase of the cycle. Explain to the woman how it is to be performed, especially if it is her first pelvic examination. Prepare the woman in the examining room by offering her a cover gown to put on and covering her lap with a privacy sheet on the examination table. Remain in the examining room throughout the examination to assist the health care provider with any procedures or specimens and to offer the woman reassurance.

Laboratory and Diagnostic Tests

Common laboratory tests that may be ordered to determine the cause of dysmenorrhea might include:

- Complete blood count to rule out anemia
- Urinalysis to rule out a bladder infection

- Pregnancy test (human chorionic gonadotropin level) to rule out pregnancy
- Cervical culture to exclude STI
- Erythrocyte sedimentation rate to detect an inflammatory process
- Stool guaiac to exclude gastrointestinal bleeding or disorders
- Pelvic and/or vaginal ultrasound to detect pelvic masses or cysts
- Diagnostic laparoscopy and/or laparotomy to visualize pathology that may account for the symptoms

What diagnostic tests might be ordered to diagnose Izzy's pelvic pain?

Nursing Management

Educating the client about the normal events of the menstrual cycle and the etiology of her pain is paramount in achieving a successful outcome. Explaining the normal menstrual cycle will teach the woman the correct terms so she can communicate her symptoms more accurately and will help dispel myths. Provide the woman with monthly graphs or charts to record menses, the onset of pain, the timing of medication, relief afforded, and coping strategies used. This involves the woman in her care and provides objective information so that therapy can be modified if necessary.

The nurse should explain in detail the dosing regimen and the side effects of the medication therapy selected. Commonly prescribed drugs include NSAIDs such as ibuprofen (Motrin), naproxen (Naprosyn), and Advil. They alleviate dysmenorrhea symptoms by decreasing intrauterine pressure and inhibiting prostaglandin synthesis, thus reducing pain (Skidmore-Roth, 2007). If pain relief is not achieved in two to four cycles, a low-dose combination oral contraceptive may be initiated. Client teaching and counseling should include information about how to take pills, side effects, and danger signs to watch for.

Encourage the woman to apply a heating pad or warm compress to alleviate menstrual cramps. Additional lifestyle changes that the woman can make to restore some sense of control and active participation in her care are listed in Teaching Guidelines 4.3.

DYSFUNCTIONAL UTERINE BLEEDING

Dysfunctional uterine bleeding (DUB) is a disorder that occurs most frequently in women at the beginning and end of their reproductive years. Defined as irregular, abnormal bleeding that occurs with no identifiable anatomic

TEACHING GUIDELINES 4.3

Tips to Manage Dysmenorrhea

- Exercise to increase endorphins and suppress prostaglandin release.
- Limit salty foods to prevent fluid retention.
- Increase water consumption to serve as a natural diuretic.
- Increase fiber intake with fruits and vegetables to prevent constipation.
- Use heating pads or warm baths to increase comfort.
- Take warm showers to promote relaxation.
- Sip on warm beverages, such as decaffeinated green tea.
- Keep legs elevated while lying down or lie on side with knees bent.
- Use stress management techniques to reduce emotional stress.
- Practice relaxation techniques to enhance ability to cope with pain.
- Stop smoking and decrease alcohol use.

Source: Nasir, 2007.

pathology, it affects 33% to 50% of women (Rackow & Arici, 2007). It is frequently associated with anovulatory cycles, which are common for the first year after menarche and later in life as women approach menopause.

The pathophysiology of DUB is related to a hormone disturbance. With anovulation, estrogen levels rise as usual in the early phase of the menstrual cycle. In the absence of ovulation, a corpus luteum never forms and progesterone is not produced. The endometrium moves into a hyperproliferative state, ultimately outgrowing its estrogen supply. This leads to irregular sloughing of the endometrium and excessive bleeding (Aeby & Frattarelli, 2006). If the bleeding is heavy enough and frequent enough, anemia can result.

DUB is similar to several other types of uterine bleeding disorders and sometimes overlaps these conditions. They include:

- Menorrhagia (abnormally long, heavy periods)
- Oligomenorrhea (bleeding occurs at intervals of more than 35 days)
- Metrorrhagia (bleeding between periods)
- Menometrorrhagia (bleeding occurs at irregular intervals with heavy flow lasting more than 7 days)
- Polymenorrhea (too frequent periods)

Etiology

The possible causes of DUB may include:

- Adenomyosis
- Pregnancy

- Hormonal imbalance
- Fibroid tumors (see Chapter 7)
- Endometrial polyps or cancer
- Endometriosis
- Intrauterine device (IUD)
- Polycystic ovary syndrome
- Morbid obesity
- Steroid therapy
- Hypothyroidism
- Blood dyscrasias/clotting disorder

Therapeutic Management

Treatment of DUB depends on the cause of the bleeding and the age of the client. When known, the underlying cause of the disorder is treated. Otherwise, the goal of treatment is to relieve the symptoms so that uterine bleeding does not interfere with a woman's normal activities or cause anemia (Dodds & Sinert, 2006).

Management of DUB might include medical care with pharmacotherapy or insertion of an IUD. Oral contraceptives are used for cycle regulation as well as contraception. They help prevent the risks associated with prolonged unopposed estrogen stimulation of the endometrium. NSAIDs and the levonorgestrel-releasing IUD (Mirena) decrease menstrual blood loss significantly (Lethaby, Cooke & Rees, 2006). The drug categories used in the treatment of DUB are:

- Estrogens: cause vasospasm of the uterine arteries to decrease bleeding
- Progestins: used to stabilize an estrogen-primed endometrium
- Oral contraceptives: regulate the cycle and suppress the endometrium
- NSAIDs: inhibit prostaglandins
- Levonorgestrel-20 Intrauterine System: suppresses endometrial growth
- Iron salts: replenish iron stores lost during heavy bleeding

If the client does not respond to medical therapy, surgical intervention might include dilation and curettage (D&C), endometrial ablation, or hysterectomy. Endometrial ablation is an alternative to hysterectomy. A thermal balloon or a laser is used to ablate the tissue, producing improvement in 90% of women (Speroff & Fritz, 2005).

Nursing Assessment

A thorough history should be taken to differentiate between DUB and other conditions that might cause vaginal bleeding, such as pregnancy and pregnancy-related conditions (abruptio placentae, ectopic pregnancy, abortion, or placenta previa); systemic conditions such as Cushing disease, blood dyscrasias, liver disease, renal disease, or thyroid disease; and genital tract pathology such as infections, tumors, or trauma (Hackley, Kriebs & Rousseau, 2007).

Assess for clinical manifestations of DUB, which commonly include vaginal bleeding between periods, irregular menstrual cycles (usually less than 28 days between cycles), infertility, mood swings, hot flashes, vaginal tenderness, variable menstrual flow ranging from scanty to profuse, obesity, acne, and diabetes. Signs of polycystic ovary syndrome might be present, since it is associated with unopposed estrogen stimulation, elevated androgen levels, and insulin resistance and is a common cause of anovulation (Torpy, 2007).

Measure orthostatic blood pressure and orthostatic pulse; a drop in pressure or pulse rate may occur with anemia. The health care provider, with the nurse assisting, performs a pelvic examination to identify any structural abnormalities.

Common laboratory tests that may be ordered to determine the cause of DUB include:

- Complete blood count to detect anemia
- Prothrombin time (PT) to detect blood dyscrasias
- Pregnancy test to rule out a spontaneous abortion or ectopic pregnancy
- Thyroid-stimulating hormone (TSH) level to screen for hypothyroidism
- Transvaginal ultrasound to measure endometrium
- Pelvic ultrasound to view any structural abnormalities
- Endometrial biopsy to check for intrauterine pathology
- D&C for diagnostic evaluation

Nursing Management

Educate the client about normal menstrual cycles and the possible reasons for her abnormal pattern. Inform the woman about treatment options. Do not simply encourage the woman to “live with it”: complications such as infertility can result from lack of ovulation; severe anemia can occur secondary to prolonged or heavy menses; and endometrial cancer can occur associated with prolonged buildup of the endometrial lining without menstrual bleeding (Rackow & Arici, 2007). Instruct her about any prescribed medications and potential side effects. For example, if high-dose estrogens are prescribed, the woman may experience nausea. Teach her to take antiemetics as prescribed and encourage her to eat small, frequent meals to alleviate nausea. Adequate follow-up and evaluation for women who do not respond to medical management is essential. See Nursing Care Plan 4.1: Overview of a Woman With Dysfunctional Uterine Bleeding (DUB).

PREMENSTRUAL SYNDROME

Premenstrual syndrome (PMS) describes a wide range of recurrent symptoms that occur during the luteal phase or last half of the menstrual cycle and resolve with the onset of menstruation (Braverman & Neinstein,

Nursing Care Plan 4.1

OVERVIEW OF A WOMAN WITH DYSFUNCTIONAL UTERINE BLEEDING (DUB)

Stacy, a 52-year-old obese woman, comes to her gynecologist with the complaint of heavy erratic bleeding. Her periods were fairly regular until about 4 months ago, and since that time they have been unpredictable, excessive, and prolonged. Stacy reports she is tired all the time, can't sleep, and feels "out of sorts" and anxious. She is fearful she has cancer.

NURSING DIAGNOSIS: Fear related to current signs and symptoms possibly indicating a life-threatening condition

Outcome Identification and Evaluation

The client will acknowledge her fears as evidenced by statements made that fear and anxiety have been lessened after explanation of diagnosis.

Interventions: Reducing Fear and Anxiety

- Distinguish between anxiety and fear to determine appropriate interventions.
- Check complete blood count and assess for possible anemia secondary to excessive bleeding to determine if fatigue is contributing to anxiety and fear. Fatigue occurs because the oxygen-carrying capacity of the blood is reduced.
- Reassure client that symptoms can be managed to help address her current concerns.
- Provide client with factual information and explain what to expect to assist client with identifying fears and help in her coping with her condition.
- Provide symptom management to reduce concerns associated with the cause of bleeding.
- Teach client about early manifestations of fear and anxiety to aid in prompt recognition and to minimize escalation of anxiety.
- Assess client's use of coping strategies in the past and reinforce use of effective ones to help control anxiety and fear.
- Instruct client in relaxation methods, such as deep breathing exercises and imagery, to provide her with additional methods for controlling anxiety and fear.

NURSING DIAGNOSIS: Deficient knowledge related to perimenopause and its management

Outcome Identification and Evaluation

The client will demonstrate understanding of her symptoms as evidenced by making health-promoting lifestyle choices, verbalizing appropriate health care practices, and adhering to measures to comply with therapy.

Interventions: Providing Patient Education

- Assess client's understanding of perimenopause and its treatment to provide a baseline for teaching and developing a plan of care.
- Review instructions about prescribed procedures and recommendations for self-care, frequently obtaining feedback from the client to validate adequate understanding of information.
- Outline link between anovulatory cycles and excessive buildup of uterine lining in perimenopausal women to assist client in understanding the etiology of her bleeding.
- Provide written material with pictures to promote learning and help client visualize what is occurring to her body during perimenopause.
- Inform client about the availability of community resources and make appropriate referrals as needed to provide additional education and support.
- Document details of teaching and learning to allow for continuity of care and further education, if needed.

2007). The American College of Obstetricians and Gynecologists (ACOG) defines premenstrual syndrome as "the cyclic occurrence of symptoms that are sufficiently severe to interfere with some aspects of life, and that appear with consistent and predictable relationship to menses" (ACOG, 2000). A woman experiencing PMS may have a

wide variety of seemingly unrelated symptoms; for that reason, it is difficult to define and more challenging to diagnose. PMS affects millions of women during their reproductive years: up to 85% of menstruating women report having one or more premenstrual symptoms, and up to 10% report disabling, incapacitating symptoms

(Campagne & Campagne, 2007). The exact cause of PMS is not known. It is thought to be related to the interaction between hormonal events and neurotransmitter function, specifically serotonin. Not all women respond to serotonin reuptake inhibitors (SSRIs), however, which implies that other mechanisms may be involved (Braverman & Neinstein, 2007).

As defined by the American Psychological Association, premenstrual dysphoric disorder (PMDD) is a more severe variant of PMS. Experts compare the difference between PMS and PMDD to the difference between a mild tension headache and a migraine (Giulio & Reissing, 2006). PMDD markedly interferes with work and school, or with social activities and relationships with others.

Therapeutic Management

Treatment of PMS is often frustrating for both patients and health care providers. Clinical outcomes can be expected to improve as a result of recent consensus on the diagnostic criteria for PMS and PMDD, data from clinical trials, and the availability of evidence-based clinical guidelines.

The management of PMS or PMDD requires a multidimensional approach because these conditions are not likely to have a single cause, and they appear to affect multiple systems within a woman's body; therefore, they are not likely to be amenable to treatment with a single therapy. To reduce the negative impact of premenstrual disorders on a woman's life, education, along with reassurance and anticipatory guidance, are needed for women to feel they have some control over their condition.



► Take NOTE!

Because there are no diagnostic tests that can reliably determine the existence of PMS or PMDD, it is the woman herself who must decide that she needs help during this time of the month. The woman must embrace multiple therapies and become an active participant in her treatment plan to find the best level of symptom relief.

Therapeutic interventions for PMS and PMDD address the symptoms because the exact cause of this condition is still unknown. Treatments may include vitamin supplements, diet changes, exercise, lifestyle changes, and medications (Box 4.2). Medications used in treating PMDD may include antidepressant and anti-anxiety drugs, diuretics, anti-inflammatory medications, analgesics, synthetic androgen agents, oral contraceptives, or GnRH agonists to regulate menses (Pavlovich-Danis, 2007).

BOX 4.2 Treatment Options for PMS and PMDD

- Lifestyle changes:
 - Reduce stress.
 - Exercise three to five times each week.
 - Eat a balanced diet and increase water intake.
 - Decrease caffeine intake.
 - Stop smoking.
 - Limit intake of alcohol.
 - Attend a PMS/women's support group.
- Vitamin and mineral supplements
 - Multivitamin daily
 - Vitamin E, 400 units daily
 - Calcium, 1,200 mg daily
 - Magnesium, 200 to 400 mg daily
- Medications
 - NSAIDs taken a week prior to menses
 - Oral contraceptives (low dose)
 - Antidepressants (SSRIs)
 - Anxiolytics (taken during luteal phase)
 - Diuretics to remove excess fluid
 - Progestins
 - Gonadotropin-releasing hormone (GnRH agonists)
 - Danazol (androgen hormone inhibits estrogen production)

Many women use dietary supplements and herbal remedies for their menstrual health and treating their bleeding disorders, although there has been little research to demonstrate their efficacy. Some alternative therapies used might include calcium, magnesium, vitamin B6, evening primrose oil, vitex agnus castus, ginkgo biloba, viburnum, dandelion, stinging nettle, burdock, raspberry leaf, skullcap, and St. John's wort (Canning, Waterman & Dye, 2006). Although research hasn't validated alternative therapy's efficacy, it is important for the nurse to be aware of the alternative products that many women choose to use.

Nursing Assessment

Although little consensus exists in the medical literature and among researchers about what constitutes PMS and PMDD, the physical and psychological symptoms are very real. The extent to which the symptoms debilitate or incapacitate a woman is highly variable.

There are more than 200 symptoms assigned to PMS, but irritability, tension, and dysphoria are the most prominent and consistently described (Moreno & Giesel, 2006). To establish the diagnosis of PMS, elicit a description of cyclic symptoms occurring before the woman's menstrual period. The woman should chart her symptoms daily for two cycles. These data will help demonstrate symptoms

clustering around the luteal phase of ovulation, with resolution after bleeding starts. Ask the woman to bring her list of symptoms to the next appointment. Symptoms can be categorized using the following:

- A: anxiety: difficulty sleeping, tenseness, mood swings, clumsiness
- C: craving: headache, cravings for sweets, salty foods, chocolate
- D: depression: feelings of low self-esteem, anger, easily upset
- H: hydration: weight gain, abdominal bloating, breast tenderness
- O: other: hot flashes or cold sweats, nausea, change in bowel habits, aches or pains, dysmenorrhea, acne breakout (Pavlovich-Danis, 2007)

The ACOG diagnostic criteria for PMS consist of having at least one of the following affective and somatic symptoms during the 5 days before menses in each of the three previous cycles:

- Affective symptoms: depression, angry outbursts, irritability, anxiety
- Somatic symptoms: breast tenderness, abdominal bloating, edema, headache
- Symptoms relieved from days 4 to 13 of the menstrual cycle (ACOG, 2000)

In PMDD, the main symptoms are mood disorders such as depression, anxiety, tension, and persistent anger or irritability. Physical symptoms such as headache, joint and muscle pain, lack of energy, bloating, and breast tenderness are also present (Hsiao & Liu, 2007). It is estimated that 20% to 40% of reproductive-age women experience premenstrual symptoms that meet the ACOG criteria for PMS and up to 10% meet the diagnostic criteria for PMDD (Futterman & Rapkin, 2006).

According to the American Psychiatric Association, a woman must have at least five of the typical symptoms to be diagnosed with PMDD (Andoisek & Rapkin, 2007). These must occur during the week before and a few days after the onset of menstruation and must include one or more of the first four symptoms:

1. Affective lability: sadness, tearfulness, irritability
2. Anxiety and tension
3. Persistent or marked anger or irritability
4. Depressed mood, feelings of hopelessness
5. Difficulty concentrating
6. Sleep difficulties
7. Increased or decreased appetite
8. Increased or decreased sexual desire
9. Chronic fatigue
10. Headache
11. Constipation or diarrhea
12. Breast swelling and tenderness (Htay & Aung, 2006)

Nursing Management

Educate the client about the management of PMS or PMDD. Advise her that lifestyle changes often result in significant symptom improvement without pharmacotherapy. Encourage women to eat a balanced diet that includes nutrient-rich foods to avoid hypoglycemia and associated mood swings. Encourage adolescent girls to participate in aerobic exercise three times a week to promote a sense of well-being, decrease fatigue, and reduce stress. Administer calcium (1,200 to 1,600 mg/day), magnesium (400 to 800 mg/day), and vitamin B6 (50 to 100 mg/day) as prescribed. In some studies, these nutrients have been shown to decrease the intensity of PMS symptoms. NSAIDs may be useful for painful physical symptoms and spironolactone (Aldactone) may help with bloating and water retention. Herbs such as Vitex (chaste tree berry), evening primrose, and SAM-e may be recommended; although not harmful, not all herbs have enough clinical or research evidence to document their safety or efficacy (Schuiling & Likis, 2006).

A recent research study proposes calcium (1,600 mg/day) and vitamin D (400 IU/day) supplementation in adolescents and women in an effort to prevent PMS (Clayton, 2008).

Explain the relationship between cyclic estrogen fluctuation and changes in serotonin levels and how the different management strategies help maintain serotonin levels, thus improving symptoms. It is important to rule out other conditions that might cause erratic or dysphoric behavior. If the initial treatment regimen does not work, explain to the woman that she should return for further testing. Behavioral counseling and stress management might help women regain control during these stressful periods. Reassuring the woman that support and help are available through many community resources/support groups can be instrumental in her acceptance of this monthly disorder. Nurses can be a very calming force for many women experiencing PMS or PMDD.



► Take NOTE!

Adolescents and women who experience more extensive emotional symptoms with PMS should be evaluated for PMDD, as they may require antidepressant therapy.

▶ ENDOMETRIOSIS

Endometriosis is one of the most common gynecologic diseases, affecting more than 5.5 million women in the United States. In this condition, bits of functioning endometrial tissue are located outside of their normal site, the uterine cavity. This endometrial tissue is commonly found

attached to the ovaries, fallopian tubes, the outer surface of the uterus, the bowels, the area between the vagina and the rectum (rectovaginal septum), and the pelvic side wall (Fig. 4.1). The places where the tissue attaches are called implants, or lesions. Endometrial tissue found outside the uterus responds to hormones released during the menstrual cycle in the same way as endometrial lining within the uterus.

At the beginning of the menstrual cycle, when the lining of the uterus is shed and menstrual bleeding begins, these abnormally located implants swell and bleed also. In short, the woman with endometriosis experiences several “mini-periods” throughout her abdomen, wherever this endometrial tissue exists.

Think back to Izzy, with her progressive pelvic pain and infertility concerns. After a pelvic examination, her health care provider suspects she has endometriosis.

Etiology and Risk Factors

It is not currently known why endometrial tissue becomes transplanted and grows in other parts of the body. Several theories exist, but to date none has been scientifically proven. However, several factors that increase a woman's risk of developing endometriosis have been identified:

- Increasing age
- Family history of endometriosis in a first-degree relative
- Short menstrual cycle (less than 28 days)
- Long menstrual flow (more than 1 week)
- Young age of menarche (younger than 12)
- Few (one or two) or no pregnancies (Speroff & Fritz, 2005)

Therapeutic Management

Therapeutic management of the client with endometriosis needs to take into consideration the following factors: severity of symptoms, desire for fertility, degree of disease, and the client's therapy goals. The aim of therapy is to suppress levels of estrogen and progesterone, which cause the endometrium to grow. Treatment can include surgery or medication (Table 4.2).

Nursing Assessment

Nurses encounter women with endometriosis in a variety of settings: community health settings, schools, clinics, day surgical centers, and hospitals. Health care professionals must not trivialize or dismiss the concerns of these women, because early recognition is essential to preserve fertility.

Health History

Obtain a health history and elicit a description of signs and symptoms to determine risk factors. Endometriosis is often asymptomatic, but it can be a severe and debilitating condition. It typically is chronic and progressive. Assess the client for clinical manifestations, which include:

- Infertility
- Pain before and during menstrual periods
- Pain during or after sexual intercourse
- Painful urination
- Depression
- Fatigue
- Painful bowel movements
- Chronic pelvic pain
- Hypermenorrhea (heavy menses)
- Pelvic adhesions




FIGURE 4.1 Common sites of endometriosis formation.

TABLE 4.2 TREATMENT OPTIONS FOR ENDOMETRIOSIS

Therapy Options	Comment
Surgical intervention	
Conservative surgery	Removal of implants/lesions using laser, cautery, or small surgical instruments. This intervention will reduce pain and allows pregnancy to occur in the future.
Definitive surgery	Abdominal hysterectomy, with or without bilateral salpingo-oophorectomy. Will eliminate pain but will leave a woman unable to become pregnant in the future.
Medication therapy	
NSAIDs	First-line treatment to reduce pain; taken early when premenstrual symptoms are first felt
Oral contraceptives	Suppresses cyclic hormonal response of the endometrial tissue
Progestogens	Used to cast off the endometrial cells and thus destroy them
Antiestrogens	Suppresses a woman's production of estrogen, thus stopping the menstrual cycle and preventing further growth of endometrium
Gonadotropin-releasing hormone analogues (GnRH-a)	Suppresses endometriosis by creating a temporary pseudomenopause
Danazol (Danocrine)	A synthetic androgen (male sex hormone) used typically as a second-line treatment of endometriosis. Disrupts the action of the pituitary gland by suppressing the output of some hormones, thus reducing estrogen, halting menstruation, and resulting in the growth of facial hair and acne.

- Irregular and more frequent menses
- Premenstrual vaginal spotting (Schuiling & Likis, 2006)

The two most common symptoms are infertility and pain. Endometriosis occurs in 38% of infertile women and in 71% to 87% of women with chronic pelvic pain (Aeby & Hraoka, 2006). About 30% to 40% of women with this condition are infertile, making it one of the top three causes of female infertility (NICHD, 2006).

What are the two most common symptoms experienced by women with endometriosis? Is Izzy's profile typical? As a nurse, what would be your role in Izzy's continued workup?

Physical Examination and Laboratory and Diagnostic Tests

The pelvic examination typically correlates with the extent of the endometriosis. The usual finding is nonspecific pelvic tenderness. The hallmark finding is the presence of tender nodular masses on the uterosacral ligaments,

the posterior uterus, or the posterior cul-de-sac (Saul & Dave, 2006).

After a thorough history and a pelvic examination, the health care practitioner may suspect endometriosis, but the only certain method of diagnosing it is by seeing it. Pelvic or transvaginal ultrasound is used to assess pelvic organ structures. However, a laparoscopy is needed to diagnose endometriosis. Laparoscopy is the direct visualization of the internal organs with a lighted instrument inserted through an abdominal incision. A tissue biopsy of the suspected implant taken at the same time and examined microscopically confirms the diagnosis.

Nurses can play a role by offering a thorough explanation of the condition and explaining why tests are needed to diagnose endometriosis. The nurse can set up appointments for imaging studies and laparoscopy.

Nursing Management

In addition to the interventions outlined above, the nurse should encourage the client to adopt healthy lifestyle habits with respect to diet, exercise, sleep, and stress management. Referrals to support groups and Internet resources

can help the woman to understand this condition and to cope with chronic pain. A number of organizations provide information about the diagnosis and treatment of endometriosis and offer support to women and their families (Box 4.3).

After completing several diagnostic tests, Izzy is diagnosed with endometriosis. She asks you about her chances of becoming pregnant and becoming pain-free. What treatment options would you explain to Izzy? What information can you give about her future childbearing ability?

Infertility

Infertility is defined as the inability to conceive a child after 1 year of regular sexual intercourse unprotected by contraception, or the inability to carry a pregnancy to term (Covington & Burns, 2006). Secondary infertility is the inability to conceive after a previous pregnancy. Many people take the ability to conceive and produce a

BOX 4.3 Organizations and Web Resources to Assist the Client With Endometriosis

- American College of Obstetricians and Gynecologists (ACOG): www.acog.org or e-mail at resources@acog.org
- American Society of Reproductive Medicine: www.asrm.org or e-mail at asrm@asrm.org
- Center for Endometriosis Care: <http://www.centerforendo.com/>
- Endometriosis Association: www.endometriosisassn.org or www.KillerCramps.org
- Endometriosis Association support groups: e-mail at support@endometriosisassn.org
- NICHD Information Resource Center: www.nichd.nih.gov or e-mail at NICHDClearinghouse@mail.nih.gov
- National Women's Health Information Center (Dept. of Health and Human Services): <http://www.4women.gov>

EVIDENCE-BASED PRACTICE

The Effectiveness of Danazol Compared to Placebo or No Treatment in the Treatment of the Symptoms and Signs (Other than Infertility) of Endometriosis in Women of Reproductive Age

● Study

Endometriosis is defined as the presence of endometrial tissue (stromal and glandular) outside the normal uterine cavity. Conventional medical and surgical treatments for endometriosis aim to remove or decrease deposits of ectopic endometrium. The observation that hyperandrogenic states (an excess of male hormone) induce atrophy of the endometrium has led to the use of androgens in the treatment of endometriosis. Danazol is one of these treatments. The efficacy of danazol is based on its ability to produce a high-androgen/low-estrogen environment (a pseudomenopause), which results in the atrophy of endometriotic implants and thus an improvement in painful symptoms.

Only four trials met the inclusion criteria, and two authors independently extracted data from these trials. All four trials compared danazol to placebo. Two trials used danazol as sole therapy and two trials used danazol as an adjunct to surgery. Although the main outcome was pain improvement, other data relating to laparoscopic scores and hormonal parameters were also collected.

▲ Findings

Treatment with danazol was effective in relieving painful symptoms related to endometriosis when compared to placebo. Laparoscopic scores were improved with danazol treatment when compared with either placebo or no treatment. Side effects were more commonly reported in the patients receiving danazol than those receiving placebo. Thus, danazol is effective in treating the symptoms and signs of endometriosis. However, its use is limited by the occurrence of androgenic side effects.

■ Implications for Nursing Practice

According to the results of the study, danazol is an effective treatment for relieving painful symptoms of endometriosis, but it has side effects. As a nurse, it is important to educate the patient about these; they may include clitoral enlargement and masculinization. In addition, the response to the drug may take several weeks or months. Women should be cautioned to report yellowing of the skin (jaundice), fluid retention, shortness of breath, and changes in vaginal bleeding. It is important to stress that there are several effective therapies to treat endometriosis if the side effects are problematic with danazol.

child for granted, but infertility affects over 6 million Americans, or 15% of the reproductive-age population, according to the American Society for Reproductive Medicine (ASRM, 2007). Infertility is a widespread problem that has an emotional, social, and economic impact on couples. Nurses must recognize infertility and understand its causes and treatment options so that they can help couples understand the possibilities as well as the limitations of current therapies. Recent studies found that women wished to be treated with respect and dignity and given appropriate information and support. They wanted their distress recognized and they wanted to feel cared for and to have confidence in health care professionals in situations where outcomes were uncertain. The caring aspect of professional nursing is an essential component of meeting the special needs of these couples (Redshaw, Hockley & Davidson, 2007). Prevention of infertility through education should also be incorporated into any client–nurse interaction.

Cultural Considerations

Cross-culturally, the expectation for couples to reproduce is an accepted norm and the inability to conceive may be considered a violation of this cultural norm. In this context, infertility represents a crisis for the couple. The manner in which different cultures, ethnic groups, and religious groups perceive and manage infertility may be very different. For example, many African-Americans believe that assisted reproductive techniques are unnatural and that they remove the spiritual or divine nature of creation from conception. For this reason, they may seek spiritual rather than medical assistance when trying to conceive. The Hispanic culture believes that children validate the marriage, so families are typically large. Like the African-American culture, Hispanics are very spiritual and may consider infertility a test of faith and seek spiritual counseling.

Religion often influences cultural factors and for this reason may also be considered when pursuing treatment for infertility. In the Jewish religion procreation is felt to be an obligation and a responsibility. Roman Catholics have a very restrictive view on the use of assisted reproductive technologies since in their view procreation cannot be separated from the relationship between parents. Thus, children must be created by the physical union between husband and wife and conceived through sexual intercourse (Schenker, 2005). Nurses must be cognizant of the client's cultural and religious background and how it may dictate which, if any, reproductive treatment options are chosen. Nurses need to include this awareness in their counseling of infertile couples.

Etiology and Risk Factors

Multiple known and unknown factors affect fertility. Female-factor infertility is detected in about 40% of cases,

male-factor infertility in about 40% of cases. The remaining 20% fall into a category of combined (both male and female factors) or unexplained infertility. In women, ovarian dysfunction (40%) and tubal/pelvic pathology (40%) are the primary contributing factors to infertility (ASRM, 2007).

Risk factors for infertility include:

- For women:
 - Overweight or underweight (can disrupt hormone function)
 - Hormonal imbalances leading to irregular ovulation
 - Fibroids
 - Tubal blockages
 - Reduced oocyte quality
 - Chromosomal abnormalities
 - Congenital anomalies of the cervix and uterus
 - Immune system disorders
 - Chronic illnesses such as diabetes, thyroid disease, asthma
 - STIs
 - Age older than 27
 - Endometriosis
 - History of PID
 - Smoking and alcohol consumption
 - Multiple miscarriages
 - Psychological stress (Kelly-Weeder & O'Conner, 2006)
- For men:
 - Exposure to toxic substances (lead, mercury, x-rays)
 - Cigarette or marijuana smoke
 - Heavy alcohol consumption
 - Use of prescription drugs for ulcers or psoriasis
 - Exposure of the genitals to high temperatures (hot tubs or saunas)
 - Hernia repair
 - Frequent long-distance cycling
 - STI
 - Undescended testicles (cryptorchidism)
 - Mumps after puberty (Ficorelli & Weeks, 2007)

Therapeutic Management

The test results are presented to the couple and different treatment options are suggested. The majority of infertility cases are treated with drugs or surgery. Various ovulation-enhancement drugs and timed intercourse might be used for the woman with ovulation problems. The woman should understand the drug's benefits and side effects before consenting to take them. Depending on the type of drug used and the dosage, some women may experience multiple births. If the woman's reproductive organs are damaged, surgery can be done to repair them. Still other couples might opt for the hi-tech approaches of artificial insemination (Fig. 4.2), in vitro fertilization (IVF; Fig. 4.3), and egg donation or contract for a gestational




FIGURE 4.2 Artificial insemination. Sperm are deposited next to the cervix (A) or injected directly into the uterine cavity (B).

carrier or surrogate (Grainger, Frazier & Rowland, 2006). Table 4.3 lists selected infertility options.

Nursing Assessment

Infertile couples are under tremendous pressure and often keep the problem a secret, considering it to be very personal. The couple is often beset by feelings of inadequacy and guilt, and many are subject to pressures from both family and friends. As their problem becomes more chronic, they may begin to blame one another, with consequent marital discord. Seeking help is often a very difficult step for them, and it may take a lot of courage to discuss something about which they feel deeply embarrassed or upset. The nurse working in this specialty setting must be aware of the conflict and problems couples present with and must be very sensitive to their needs.

A full medical history should be taken from both partners, along with a physical examination. The data needed for the infertility evaluation are very sensitive and of a personal nature, so the nurse must use very professional interviewing skills.

There are numerous causes of and contributing factors to infertility, so it is important to use the process of elimination, determining what problems don't exist to better comprehend the problems that do exist. At the first visit, a plan of investigation is outlined and a complete health history is taken. This first visit forces many couples to confront the reality that their desired pregnancy may not occur naturally. Alleviate some of the anxiety associated with diagnostic testing by explaining the timing and reasons for each test.

Assessing Male Factors

The initial screening evaluation for the male partner should include a reproductive history and a semen analysis. From the male perspective, three things must happen for conception to take place: there must be an adequate number of sperm; those sperm must be healthy and mature; and the sperm must be able to penetrate and fertilize the egg. Normal males need to have more than 20 million sperm per milliliter with greater than 50% motility (WHO, 2007). Semen analysis is the most important indicator of male fertility. The man should abstain from




FIGURE 4.3 Steps involved in in vitro fertilization. (A) Ovulation. (B) Capture of the ova (done here intra-abdominally). (C) Fertilization of ova and growth in culture medium. (D) Insertion of fertilized ova into uterus.

TABLE 4.3 SELECTED TREATMENT OPTIONS FOR INFERTILITY

Procedure	Comments	Nursing Considerations
Fertility drugs		
Clomiphene citrate (Clomid)	A nonsteroidal synthetic antiestrogen used to induce ovulation	Nurse can advise the couple to have intercourse every other day for 1 week starting after day 5 of medication.
Human menopausal gonadotropin (HMG); Pergonal	Induces ovulation by direct stimulation of ovarian follicle	Same as above
Artificial insemination		
	The insertion of a prepared semen sample into the cervical os or intrauterine cavity Enables sperm to be deposited closer to improve chances of conception Husband or donor sperm can be used	Nurse needs to advise couple that the procedure might need to be repeated if not successful the first time.
Assisted reproductive technologies*		
In vitro fertilization (IVF)	Oocytes are fertilized in the lab and transferred to the uterus. Usually indicated for tubal obstruction, endometriosis, pelvic adhesions, and low sperm counts	Nurse advises woman to take medication to stimulate ovulation so the mature ovum can be retrieved by needle aspiration.
Gamete intrafallopian transfer (GIFT)	Oocytes and sperm are combined and immediately placed in the fallopian tube so fertilization can occur naturally. Requires laparoscopy and general anesthesia, which increases risk	Nurse needs to inform couple of risks and have consent signed.
Intracytoplasmic sperm injection (ICSI)	One sperm is injected into the cytoplasm of the oocyte to fertilize it. Indicated for male factor infertility.	Nurse needs to inform the male that sperm will be aspirated by a needle through the skin into the epididymis.
Donor oocytes or sperm	Eggs or sperm are retrieved from a donor and the eggs are inseminated; resulting embryos are transferred via IVF. Recommended for women older than 40 and those with poor-quality eggs.	Nurse needs to support couple in their ethical/religious discussions prior to deciding.
Gestational carrier (surrogacy)	Laboratory fertilization takes place and embryos are transferred to the uterus of another woman, who will carry the pregnancy. Medical-legal issues have resulted over the “true ownership” of the resulting infant.	Nurse should encourage an open discussion regarding implications of this method with the couple.

*When other options have been exhausted, these are considered.

sexual activity for 24 to 48 hours before giving the sample. For a semen examination, the man is asked to produce a specimen by ejaculating into a specimen container and delivering it to the laboratory for analysis within 1 to 2 hours. When the specimen is brought to the laboratory, it is analyzed for volume, viscosity, number of sperm, sperm viability, motility, and sperm shape. If semen param-

eters are normal, no further male evaluation is necessary (Quallich, 2006).

The physical examination routinely includes:

- Assessment for appropriate male sexual characteristics, such as body hair distribution, development of the Adam's apple, and muscle development

- Examination of the penis, scrotum, testicles, epididymis, and vas deferens for abnormalities (e.g., nodules, irregularities, varicocele)
- Assessment for normal development of external genitalia (small testicles)
- Performance of a digital internal examination of the prostate to check for tenderness or swelling (DeMasters, 2004)

Assessing Female Factors

The initial assessment of the woman should include a thorough history of factors associated with ovulation and the pelvic organs. Diagnostic tests to determine female infertility may include:

- Assessment of ovarian function
 - Menstrual history: regularity of cycles
 - Ovulation predictor kits used midcycle
 - Urinary LH level
 - Clomiphene citrate challenge test
 - Endometrial biopsy to document luteal phase
- Assessment of pelvic organs
- Papanicolaou (Pap) smear to rule out cervical cancer or inflammation
- Cervical culture to rule out Chlamydia infection
- Postcoital testing to evaluate sperm–cervical mucus interaction
- Ultrasound to assess pelvic structures
- Hysterosalpingography to visualize structural defects
- Laparoscopy to visualize pelvic structures and diagnose endometriosis

Laboratory and Diagnostic Testing

The diagnostic procedures that should be done during an infertility workup should be guided by the couple's history. They generally proceed from less to more invasive tests.

Home Ovulation Predictor Kits

Home ovulation predictor kits contain monoclonal antibodies specific for LH and use the ELISA test to determine the amount of LH present in the urine. A significant color change from baseline indicates the LH surge and presumably the most fertile day of the month for the woman.

Clomiphene Citrate Challenge Test

The clomiphene citrate challenge test is used to assess a woman's ovarian reserve (ability of her eggs to become fertilized). FSH levels are drawn on cycle day 3 and on cycle day 10 after the woman has taken 100 mg clomiphene citrate on cycle days 5 through 9. If the FSH level is greater than 15, the result is considered abnormal and the likelihood of conception with her own eggs is very low (Schuiling & Likis, 2006).

Endometrial Biopsy

Another assessment of ovulation that indicates whether the secretion of progesterone is adequate is an endometrial

biopsy. A strip of endometrial tissue is removed just before menstruation. Histologic documentation of secretory endometrial development implies that ovulation has taken place. An endometrium that does not conform to the normal histologic pattern indicates a defect in the luteal phase.

Postcoital Testing

Postcoital testing is done to assess the receptivity of the cervical mucus to sperm. Cervical mucus from the woman is examined 2 to 8 hours after intercourse during the expected time of ovulation, and the number of live, motile sperm present is assessed. Cervical mucus is also evaluated for stretchability (spinnbarkeit) and consistency (Alexander et al., 2007). The results are described in Comparison Chart 4.1.

Hysterosalpingogram

In a hysterosalpingogram, 3 to 10 mL of an opaque contrast medium is slowly injected through a catheter into the endocervical canal so that the uterus and tubes can be visualized during fluoroscopy and radiography. If the fallopian tubes are patent, the dye will ascend upward to distend the uterus and the tubes and will spill out into the peritoneal cavity (Fig. 4.4).

Laparoscopy

A laparoscopy is usually performed early in the menstrual cycle. During the procedure, an endoscope is inserted through a small incision in the anterior abdominal wall. Visualization of the peritoneal cavity in an infertile woman may reveal endometriosis, pelvic adhesions, tubal occlusion, fibroids, or polycystic ovaries (DeSutter, 2006).

Nursing Management

Nurses play an important role in the care of infertile couples. They are pivotal educators about preventive health care. There are a number of potentially modifiable risk

COMPARISON CHART 4.1 NORMAL VERSUS ABNORMAL POSTCOITAL TEST RESULTS

Normal	Abnormal
Normal amounts of sperm are seen in the sample.	No sperm or a large percentage of dead sperm are seen in the sample.
Sperm are moving forward through the cervical mucus.	Sperm are clumped.
The mucus stretches at least 2 in (5 cm).	Mucus cannot stretch 2 in (5 cm).
The mucus dries in a fernlike pattern.	Mucus does not dry in a fernlike pattern.

Source: DeSutter, 2006.




FIGURE 4.4 Insertion of a dye for a hysterosalpingogram. The contrast dye outlines the uterus and fallopian tubes on an x-ray to demonstrate patency.

factors associated with the development of impaired fertility in women, and women need to be aware of these risks to institute change. The nurse is most effective when he or she offers care and treatment in a professional manner and regards the couple as valued and respected individuals. The nurse's focus must encompass the whole person, not just the results of the various infertility studies. Throughout the entire process, the nurse's role is to provide information, anticipatory guidance, stress management, and counseling. The couple's emotional distress is usually very high, and the nurse must be able to recognize that anxiety and provide emotional support. The nurse may need to refer couples to a reproductive endocrinologist or surgeon, depending on the problem identified.

There is no absolute way to prevent infertility per se because so many factors are involved in conception. Nurses can be instrumental in educating men and women about the factors that contribute to infertility. The nurse can also outline the risks and benefits of treatments so that the couple can make an informed decision.

With advances in genetics and reproductive medicine also come a myriad of ethical, social, and cultural issues that will affect the couple's decisions. With this in mind, provide an opportunity for the couple to make informed decisions in a nondirective, nonjudgmental environment. It is important to encourage couples to remain optimistic throughout investigation and treatment. Through the use of advocacy and anticipatory guidance, assist and support couples through the diagnosis and treatment of infertility (Jenkins & Jenkins, 2006).

Finances and insurance coverage often dictate the choice of treatment. Help couples decipher their insurance coverage and help them weigh the costs of various procedures by explaining what each will provide in terms of information about their infertility problems. Assisting them to make a priority list of diagnostic tests and potential treatment options will help the couple plan their financial strategy.

Many infertile couples are not prepared for the emotional roller coaster of grief and loss during infertility treatments. Financial concerns and coping as a couple are

BOX 4.4 Organizations and Web Resources to Assist the Client With Infertility

- **Resolve:** A nationwide network of chapters dedicated to providing education, advocacy, and support for men and women facing infertility. They provide a helpline, medical referral services, and a member-to-member contact system. (<http://www.resolve.org>)
- **American Society of Reproductive Medicine (ASRM):** Provides fact sheets and other resources on infertility, treatments, insurance, and other issues (<http://www.asrm.org>)
- **International Counsel on Infertility (INCIID):** Provides information about infertility, support forums, and a directory of infertility specialists (<http://www.inciid.org>)
- **American Fertility Association:** Offers education, referrals, research, support, and advocacy for couples dealing with infertility (<http://www.americaninfertility.org>)
- **Bertarelli Foundation: The Human Face of Infertility:** Aims to promote and improve understanding of infertility by offering resources (<http://www.bertarelli.edu>)
- **International Consumer Support for Infertility:** An international network engaged in advocacy on behalf of infertile couples via fact sheets and information (<http://www.icsi.ws>)

two major areas of stress when treatment is undertaken. During the course of what may be months or even years of infertility care, it is essential to develop a holistic approach to nursing care. Stress management and anxiety reduction need to be addressed, and referral to a peer support group such as Resolve might be in order (Box 4.4).

► Consider THIS!

We had been married for 3 years and wanted to start a family, but much to our dismay nothing happened after a year of trying. I had some irregular periods and was finally diagnosed with endometriosis and put on Clomid. After 3 years of taking Clomid on and off, I went to a fertility expert. The doctor lasered the endometriosis tissue, sent air through my tubes to make sure they were patent, and put me back on Clomid, but still with no luck. Finally, 2 years later, we were put on an IVF waiting list and prayed we would have the money for the procedure when we were chosen. By then I felt a failure as a woman. We then decided that it was more important for us to be parents than it was for me to be pregnant, so we considered adoption. We tried for another year without any results.

We went to the adoption agency to fill out the paperwork for the process to begin. Our blood was

(continued)

► **Consider THIS!** *(continued)*

taken and we waited for an hour, wondering the whole time why it was taking so long for the results. The nurse finally appeared and handed a piece of paper to me with the word “positive” written on it. I started to cry tears of joy, for a pregnancy had started and our long journey of infertility was finally ending. Thoughts: For many women the dream of having a child is not easily realized. Infertility can affect self-esteem, disrupt relationships, and result in depression. This couple experienced many years of frustration in trying to have a family. What help can be offered to couples during this time? What can be said to comfort the woman who feels she is a failure?

Contraception

In the United States, there are approximately 62 million women in their childbearing years, ages 15 to 44. Overall, 64% of those 60 million women use contraception, but still more than 3 million unintended pregnancies occur every year (CDC, 2006). Although numerous fertility control methods are available, the United States continues to have a higher unintended pregnancy rate than other Western countries. Every minute of every day, 10 people become infected with HIV, most through heterosexual contact; 190 women conceive an unwanted pregnancy; 1 woman dies from a pregnancy-related cause; and 40 women undergo unsafe abortions, as outlined in the UNFPA State of the World Population 2006 Report. Much of this suffering could be prevented by access to safe, efficient, appropriate, modern contraception for everyone who wants it (UNFPA, 2007).

Contraception is any method that prevents conception or childbirth. A woman's reproductive life spans almost 40 years, and throughout those years, a variety of contraceptive methods may be used. Oral contraceptives, sterilization of the female, and the male condom are the most popular methods in the United States (Alan Guttmacher Institute, 2007).

Couples must decide which method is appropriate for them to meet their changing contraceptive needs throughout their life cycles. Nurses can educate and assist couples during this selection process. This part of the chapter will outline the most common birth control methods available.

In an era when many women wish to delay pregnancy and avoid STIs, choices are difficult. There are numerous methods available today, and many more will be offered in the near future. The ideal contraceptive method for many women would have to have the following characteristics: ease of use, safety, effectiveness, minimal side effects, “naturalness,” nonhormonal method, and immediate reversibility (Samra & Wood, 2006). Currently, no one contraceptive method offers everything. Box 4.5 out-

BOX 4.5 Outline of Contraceptive Methods

Reversible Methods

Behavioral

- Abstinence
- Fertility awareness
- Withdrawal (coitus interruptus)
- Lactational amenorrhea method (LAM)

Barrier

- Condom (male and female)
- Diaphragm
- Cervical cap
- Sponge

Hormonal

- Oral contraceptives
- Injectable contraceptive
- Transdermal patches
- Vaginal ring
- Implantable contraceptives
- Intrauterine systems
- Emergency contraceptives

Permanent Methods

- Tubal ligation for women
- Vasectomy for men

lines the contraceptive methods available today. Table 4.4 provides a detailed summary of each type, including information on failure rates, advantages, disadvantages, STI protection, and danger signs.

Types of Contraceptive Methods

Contraceptives methods can be divided into three types: behavioral methods, barrier methods, and hormonal methods.

Behavioral Methods

Behavioral methods refer to any natural contraceptive method that does not require hormones, pharmaceutical compounds, physical barriers, or surgery to prevent pregnancy. These methods require couples to take an active role in preventing pregnancy through their sexual behaviors.

Abstinence

Abstinence (not having vaginal or anal intercourse) is one of the least expensive forms of contraception and has been used for thousands of years. Basically, pregnancy cannot occur if sperm is kept out of the vagina. It also reduces the risk of contracting HIV/AIDS and other STIs, unless body fluids are exchanged through oral sex; however, some infections, like herpes and HPV, can be passed by skin-to-skin contact. There are many pleasurable

(text continues on page 000)

TABLE 4.4 SUMMARY OF CONTRACEPTIVE METHODS

Type	Description	Failure Rate	Pros	Cons	STI Protection	Danger Signs	Comments
Abstinence	Refrain from sexual activity	None	Costs nothing	Difficult to maintain	100%	None	Must be joint couple decision
Fertility awareness	Refrain from sex during fertile period	25%	No side effects; acceptable to most religious groups	High failure rate with incorrect use	None	None	Requires high level of couple commitment
Withdrawal (coitus interruptus)	Man withdraws before ejaculation	27%	Involves no devices and is always available	Requires considerable self-control by the man	None	None	Places woman in trusting and dependent role
Lactational amenorrhea method (LAM)	Uses lactational infertility for protection from pregnancy	1–2% chance of pregnancy in first 6 months	No cost; not coitus-linked	Temporary method; effective for only 6 months after giving birth	None	None	Mother must breastfeed infant on demand without supplementation for 6 months
Male condom	Thin sheath placed over an erect penis, blocking sperm	15%	Widely available; low cost; physiologically safe	Decreased sensation for man; interferes with sexual spontaneity; breakage risk	Provides protection against STIs	Latex allergy	Couple must be instructed on proper use of condom
Female condom	Polyurethane sheath inserted vaginally to block sperm	21%	Use controlled by woman; eliminates postcoital drainage of semen	Expensive for frequent use; cumbersome; noisy during sex act; for single use only	Provides protection against STIs	Allergy to polyurethane	Couple must be instructed on proper use of condom
Diaphragm with spermicide	Shallow latex cup with spring mechanism in its rim to hold it in place in the vagina	16%	Does not use hormone; considered medically safe; provides some protection against cervical cancer	Requires accurate fitting by health care professional; increase in UTIs	None	Allergy to latex, rubber, polyurethane, or spermicide. Report symptoms of toxic shock syndrome. Change size if excessive weight gain or loss.	Woman must be taught to insert and remove diaphragm correctly

(continued)

TABLE 4.4 SUMMARY OF CONTRACEPTIVE METHODS (continued)

Type	Description	Failure Rate	Pros	Cons	STI Protection	Danger Signs	Comments
Cervical cap with spermicide	Soft cup-shaped latex device that fits over base of cervix	24%	No use of hormones; provides continuous protection while in place	Requires accurate fitting by health care professional; odor may occur if left in too long	None	Irritation, allergic reaction; abnormal Pap test; risk of toxic shock syndrome	Instructions on insertion and removal must be understood by client
Sponge with spermicide	Disk-shaped polyurethane device containing a spermicide that is activated by wetting it with water	25%	Offers immediate and continuous protection for 24 hours; OTC	Can fall out of vagina with voiding; is not form-fitting in the vagina	None	Irritation, allergic reactions; toxic shock syndrome can occur if sponge left in too long	Caution woman not to leave sponge in beyond 24 hours
Oral contraceptives (combination)	A pill that suppresses ovulation by combined action of estrogen and progestin	8%	Easy to use; high rate of effectiveness; protection against ovarian and endometrial cancer	User must remember to take pill daily; possible undesirable side effects; high cost for some women; prescription needed	None	Dizziness, nausea, mood changes, high blood pressure, blood clots, heart attacks, strokes	Each woman must be assessed thoroughly to make sure she is not a smoker and does not have a history of thromboembolic disease
Oral contraceptives (progestin-only minipills)	A pill containing only progestin that thickens cervical mucus to prevent sperm from penetrating	8%	No estrogen-related side effects; may be used by lactating women; may be used by women with history of thrombophlebitis	Must be taken with meticulous accuracy; may cause irregular bleeding; less effective than combination pills	None	Irregular bleeding, weight gain, increased incidence of ectopic pregnancy	Women should be screened for history of functional ovarian cysts, previous ectopic pregnancy, hyperlipidemia prior to giving prescription

Lunelle injectable	An injectable form of progestin and estrogen given monthly	3%	Woman will regain fertility 2–3 months after last injection; no need for daily pill taking	Must make arrangements for monthly injection; possible weight gain	None	Irregular spotting; similar to oral combination pills	Screen woman's ability to schedule monthly appointment for injection
Patch (Ortho Evra)	Transdermal patch that releases estrogen and progestin into circulation	8%	Easy system to remember; very effective	May cause skin irritation where it is placed; may fall off and not be noticed and thus provide no protection	None	Less effective in women weighing more than 200 pounds	Instruct woman to apply patch every week for 3 weeks and then not to wear one during week 4
Ring (NuvaRing)	Vaginal contraceptive ring about 2 inches in diameter that is inserted into the vagina; releases estrogen and progestin	8%	Easy system to remember; very effective	May cause a vaginal discharge; can be expelled without noticing and not offer protection	None	Similar to oral contraceptives	Instruct woman to use a backup method if ring is expelled and remains out for more than 3 hours
Depo-Provera injection	An injectable progestin that inhibits ovulation	3%	Long duration of action (3 months); highly effective; estrogen-free; may be used by smokers; can be used by lactating women	Menstrual irregularities; return visit needed every 12 weeks; weight gain, headaches, depression; return to fertility delayed up to 12 months	None	If depression is a problem, this method may increase the depression.	Inform woman that fertility is delayed after stopping the injections

(continued)

TABLE 4.4 SUMMARY OF CONTRACEPTIVE METHODS (continued)

Type	Description	Failure Rate	Pros	Cons	STI Protection	Danger Signs	Comments
Implant (Implanon)	A time-release implant (one rod) of levonorgestrel for 3 years	0.05%	Long duration of action; low dose of hormones; reversible; estrogen-free	Irregular bleeding; weight gain; breast tenderness; headaches; difficulty in removal	None	If bleeding is heavy, anemia may occur.	Before insertion, assess woman to make sure she is aware that this method will produce about 3–5 years of infertility
Intrauterine systems (IUSs)	A T-shaped device inserted into the uterus that releases copper or progesterone or levonorgestrel	1%	It is immediately and highly effective; allows for sexual spontaneity; can be used during lactation; return to fertility not impaired; requires no motivation by the user after insertion	Insertion requires a skilled professional; menstrual irregularities; prolonged amenorrhea; can be unknowingly expelled; may increase the risk of pelvic infection; user must regularly check string for placement; no protection against STIs; delay of fertility after discontinuing for possibly 6 to 12 months	None	Cramps, bleeding, pelvic inflammatory disease; perforation of the uterus	Instruct woman how to locate string to check monthly for placement

Postcoital emergency contraceptives (ECs)	Combination of progestin-only pills taken within 72 hours after unprotected intercourse	80%	Provides a last chance to prevent a pregnancy	Risk of ectopic pregnancy if EC fails	None	Nausea, vomiting, abdominal pain, fatigue, headache	Inform woman that ECs do not interrupt an established pregnancy, and the sooner they are taken the more effective they are
Permanent sterilization							
Male	Sealing, tying, or cutting the vas deferens	<1%	One-time decision provides permanent sterility; short recovery time; low long-term risks	Procedures are difficult to reverse; initial cost may be high; chance of regret; some pain/discomfort after procedures	None for both	Postoperative complications: pain, bleeding, infection	Counsel both as to permanence of procedure and urge them to think it through prior to signing consent
Female	Fallopian tubes are blocked to prevent conception	<1%					

Sources: Samra, 2006; FDA, 2006; Youngkin & Davis, 2004; Hatcher, 2004.

options for sex play without intercourse (“outercourse”), such as kissing, masturbation, erotic massage, sexual fantasy, sex toys such as vibrators, and oral sex.

Many people have strong feelings about abstinence based on religious and moral beliefs. There are many good and personal reasons to choose abstinence. For some it is a way of life, while for others it is a temporary choice. Some people choose abstinence because they want to:

- Wait until they are older
- Wait for a long-term relationship
- Avoid pregnancy or STIs
- Follow religious or cultural expectations

Fertility Awareness

Fertility awareness is a natural method of contraception in which no contraceptive devices are used; instead, certain observations, techniques, and calculations are used to determine the “fertile” and the “safe” periods in a monthly menstrual cycle. There are normal physiologic changes caused by hormonal fluctuations during the menstrual cycle that can be observed and charted. This information can be used to avoid or promote pregnancy. Fertility awareness methods rely upon the following assumptions:

- A single ovum is released from the ovary 14 days before the next menstrual period. It lives approximately 24 hours.
- Sperm can live up to 5 days after intercourse. The “unsafe period” during the menstrual cycle is thus approximately 6 days: 3 days before and 3 days after ovulation. Since bodily changes start to occur before ovulation, the woman can become aware of them and not have intercourse on these days or use another method to prevent pregnancy.
- The exact time of ovulation cannot be determined, so 2 to 3 days are added to the beginning and end to avoid pregnancy.

Techniques used to determine fertility include the cervical mucus ovulation method, the basal body temperature (BBT) method, and the symptothermal method (Hatcher et al., 2004). Fertility awareness methods are moderately effective but are very unforgiving if not carried out as prescribed: not following the guidelines might cause a 27% failure or pregnancy rate per cycle (Murphy, Morgan & Likis, 2006). Fertility awareness can be used in combination with coital abstinence or barrier methods during fertile days if pregnancy is not desired.

Cervical Mucus Ovulation Method

The **cervical mucus ovulation method** is used to assess the character of the cervical mucus. Cervical mucus changes in consistency during the menstrual cycle and plays a vital role in fertilization of the egg. In the days preceding ovulation, fertile cervical mucus helps draw sperm up and into the fallopian tubes, where fertilization usually takes place. It also helps maintain the survival of sperm.

As ovulation approaches, the mucus becomes more abundant, clear, slippery, and smooth; it can be stretched between two fingers without breaking. Under the influence of estrogen, this mucus looks like egg whites. It is called *spinnbarkeit* mucus (Fig. 4.5). After ovulation, the cervical mucus becomes thick and dry under the influence of progesterone.

The cervical position can also be assessed to confirm changes in the cervical mucus at ovulation. Near ovulation, the cervix feels soft and is high/deep in the vagina, the os is slightly open, and the cervical mucus is copious and slippery (Hatcher et al., 2004).

This method works because the woman becomes aware of her body changes that accompany ovulation. When she notices them, she abstains from sexual intercourse or uses another method to prevent pregnancy. Each woman is an individual, so each woman’s unsafe time of the month is unique and thus must be individually assessed and determined.

Basal Body Temperature

The **basal body temperature** (BBT) refers to the lowest temperature reached upon waking. The woman takes her temperature orally before rising and records it on a chart. Preovulation temperatures are suppressed by estrogen, whereas postovulation temperatures are increased under the influence of heat-inducing progesterone. Temperatures typically rise within a day or two after ovulation and remain elevated for approximately 2 weeks (at which point bleeding usually begins). If using this method by itself, the woman should avoid unprotected intercourse until the BBT has been elevated for 3 days. Other fertility awareness methods should be used along with BBT for better results (Fig. 4.6).




FIGURE 4.5 Spinnbarkeit is the ability of cervical mucus to stretch a distance before breaking.




FIGURE 4.6 Basal body temperature graph. (A) The woman's temperature dips slightly at midpoint in the menstrual cycle, then rises sharply, an indication of ovulation. Toward the end of the cycle (the 24th day), her temperature begins to decline, indicating that progesterone levels are falling and that she did not conceive. (B) The woman's temperature rises at the midpoint in the cycle and remains at that elevated level past the time of her normal menstrual flow, suggesting that pregnancy has occurred. (C) There is no preovulatory dip and no rise of temperature anywhere during the cycle. This is the typical pattern of a woman who does not ovulate.

Symptothermal Method

The **symptothermal method** relies on a combination of techniques to recognize ovulation, including BBT, cervical mucus changes, alterations in the position and firmness of the cervix, and other symptoms of ovulation, such as increased libido, mittelschmerz, pelvic fullness or tenderness, and breast tenderness (Dirubbo, 2006). Combining all these predictors increases awareness of when ovulation occurs and increases the effectiveness of this method. A home predictor test for ovulation is also available in most pharmacies. It measures LH levels to pinpoint the day before or the day of ovulation. These tests are widely used for fertility and infertility regimens.

The Standard Days Method and the Two-Day Method

The **Standard Days Method (SDM)** and the Two-Day Method are both natural methods of contraception developed by Georgetown University Medical Center's Institute for Reproductive Health. Both methods provide women with simple, clear instructions for identifying fertile days. Women with menstrual cycles between 26 and 32 days long can use the SDM to prevent pregnancy by avoiding unprotected intercourse on days 8 through 19 of their cycles. An international clinical trial of the SDM showed that the method is more than 95% effective when used correctly (Sinai, Arevalo & Jennings, 2006). SDM identifies the 12-day "fertile window" of a woman's menstrual cycle. These 12 days takes into account the lifespan of the women's egg (about 24 hours) and the viability of the sperm (about 5 days) as well as the variation in the actual timing of ovulation from one cycle to another. For the Two-Day Method, women observe the presence or absence of cervical secretions by examining toilet paper or underwear or by monitoring their physical sensations. Every day, the woman asks two simple questions "Did I note any secretions yesterday?" and "Did I note any secretions today?" If the answer to either question is yes, she considers herself fertile and avoids unprotected intercourse. If the answers are no, she is unlikely to become pregnant from unprotected intercourse on that day (Sinai, Arevalo & Jennings, 2006).

To help women keep track of the days on which they should avoid unprotected intercourse, a string of 32 color-coded beads (CycleBeads) is used, with each bead representing a day of the menstrual cycle. Starting with the red bead, which represents the first day of her menstrual period, the woman moves a small rubber ring one bead each day. The brown beads are the days when pregnancy is unlikely, and the white beads represent her fertile days (Arevalo, 2007). This method has been used in underdeveloped countries for women with limited educational resources (Fig. 4.7).

Withdrawal (Coitus Interruptus)

In **coitus interruptus**, also known as withdrawal, a man controls his ejaculation during sexual intercourse and ejaculates outside the vagina. It is better known colloquially as




FIGURE 4.7 CycleBeads help women use the Standard Days Method.

“pulling out in time” or “being careful.” It is one of the oldest and most widely used means of preventing pregnancy in the world (Murphy, Morgan & Likis, 2006). The problem with this method is that the first few drops of the true ejaculate contain the greatest concentration of sperm, and if some pre-ejaculatory fluid escapes from the urethra before orgasm, conception may result. This method requires that the woman rely solely on the cooperation and judgment of the man.

Lactational Amenorrhea Method

The **lactational amenorrhea method (LAM)** is an effective temporary method of contraception used by breastfeeding mothers. Continuous breastfeeding can postpone ovulation and thus prevent pregnancy. Breastfeeding stimulates the hormone prolactin, which is necessary for milk production, and also inhibits the release of another hormone, gonadotropin, which is necessary for ovulation.

Breastfeeding as a contraceptive method can be effective for 6 months after delivery only if a woman:

- Has not had a period since she gave birth
- Breastfeeds her baby at least six times daily on both breasts
- Breastfeeds her baby “on demand” at least every 4 hours
- Does not substitute other foods for a breast-milk meal
- Provides nighttime feedings at least every 6 hours
- Does not rely on this method after 6 months (Planned Parenthood, 2007)

Barrier Methods

Barrier contraceptives are forms of birth control that prevent pregnancy by preventing the sperm from reaching the

ovum. Mechanical barriers include condoms, diaphragms, cervical caps, and sponges. These devices are placed over the penis or cervix to physically obstruct the passage of sperm through the cervix. Chemical barriers called spermicides may be used along with mechanical barrier devices. They come in creams, jellies, foam, suppositories, and vaginal films. They chemically destroy the sperm in the vagina. These contraceptives are called barrier methods because they not only provide a physical barrier for sperm, but also protect against STIs. Since the HIV/AIDS epidemic started in the early 1980s, these methods have become extremely popular.

Many of these barrier methods contain latex. Allergy to latex was first recognized in the late 1970s, and since then it has become a major health concern, with increasing numbers of people affected. According to the American Academy of Allergy, Asthma and Immunology (2007), 6% of the general population, 10% of health care workers, and 50% of spina bifida patients are sensitive to natural rubber latex. Since the late 1980s, with the establishment of policies dictating barrier requirements resulting from the HIV/AIDS epidemic, there has been an exponential increase in the use of latex gloves and condoms (Lenehan, 2004). Teaching Guidelines 4.4 provides tips for individuals with latex allergy.

TEACHING GUIDELINES 4.4

Tips for Individuals Allergic to Latex

- Symptoms of latex allergy include:
 - Skin rash, itching, hives
 - Itching or burning eyes
 - Swollen mucous membranes in the genitals
 - Shortness of breath, difficulty breathing, wheezing
 - Anaphylactic shock (OSHA, 2006)
 - Use of or contact with latex condoms, cervical caps, and diaphragms is contraindicated for men and women with a latex allergy.
 - If the female partner is allergic to latex, have the male partner apply a natural condom over the latex one.
 - If the male partner experiences penile irritation after condom use, try different brands or place the latex condom over a natural condom.
 - Use polyurethane condoms rather than latex ones.
 - Use female condoms; they are made of polyurethane.
 - Switch to another birth control method that isn't made with latex, such as oral contraceptives, intrauterine systems, Depo-Provera, fertility awareness, and other non-barrier methods.
- However, these methods do not protect against sexually transmitted infections.

Condoms

Condoms are barrier methods of contraceptives made for both males and females. The male condom is made from latex or polyurethane or natural membrane and may be coated with spermicide. Male condoms are available in many colors, textures, sizes, shapes, and thicknesses. When used correctly, the male condom is put on over an erect penis before it enters the vagina and is worn throughout sexual intercourse (Fig. 4.8). It serves as a barrier to pregnancy by trapping seminal fluid and sperm and offers protection against STIs. Condoms are not perfect barriers, though, because breakage and slippage can occur. In addition, the non-latex condoms have a higher risk of pregnancy and STIs than latex condoms (Gallo, Grimes, Lopez & Schultz, 2006).

The female condom is a polyurethane pouch inserted into the vagina. It consists of an outer and inner ring that

is inserted vaginally and held in place by the pubic bone. Some women complain that the female condom is cumbersome to use and makes noise during intercourse. Female condoms are readily available, are inexpensive, and can be carried inconspicuously by the woman. The female condom was the first woman-controlled method that offered protection against pregnancy and some STIs.

Diaphragm

The **diaphragm** is a soft latex dome surrounded by a metal spring. Used in conjunction with a spermicidal jelly or cream, it is inserted into the vagina to cover the cervix (Fig. 4.9). The diaphragm may be inserted up to 4 hours before intercourse but must be left in place for at least 6 hours afterwards. Diaphragms are available in a range of sizes and styles. The diaphragm is available only by prescription and must be professionally fitted by





FIGURE 4.8 (A) Male condom. (B) Applying a male condom. Leaving space at the tip helps to ensure the condom will not break with ejaculation. (C) The female condom. (D) Insertion technique.



FIGURE 4.9 Sample diaphragm used for measuring.

a health care professional. Women may need to be refitted with a different-sized diaphragm after pregnancy, abdominal or pelvic surgery, or weight loss or gain of 10 pounds or more. As a general rule, diaphragms should be replaced every 1 to 2 years (Female Contraception, 2006). The woman also needs to receive thorough instruction about its use and should practice putting it in and taking it out before she leaves the medical office (Fig. 4.10). Diaphragms are user-controlled, nonhormonal methods that are needed only at the time of intercourse, but they are not effective unless used correctly.

Cervical Cap

The **cervical cap** is smaller than the diaphragm and covers only the cervix; it is held in place by suction. Caps are made from silicone or latex and are used with spermicide (Fig. 4.11). The Prentif cap and the FemCap are the only cervical cap devices approved in the United States currently (Gallo, Grimes & Schultz, 2006). The cap may be inserted up to 12 hours before intercourse and provides protection for 48 hours. The cap must be kept in the vagina for 8 hours after the final act of intercourse and should be replaced every 1 to 2 years. A refitting may also be necessary when a woman experiences pregnancy, abortion, or weight changes. The dome of the cap is filled about one-third full with spermicide. Spermicide should




FIGURE 4.10 Application of a diaphragm. (A) To insert, fold the diaphragm in half, separate the labia with one hand, then insert upwards and back into the vagina. (B) To position, make certain the diaphragm securely covers the cervix. (C) To remove, hook a finger over the top of the rim and bring the diaphragm down and out.




FIGURE 4.11 A cervical cap is placed over the cervix and used with a spermicidal jelly, the same as a diaphragm.

not be applied to the rim because it might interfere with the seal that must form around the cervix. The cap is available only by prescription and must be fitted by a health care professional.

Contraceptive Sponge

The **contraceptive sponge** is a nonhormonal, non-prescription device that includes both a barrier and a spermicide. When it was removed from the market in 1995, it was the most popular over-the-counter female contraceptive in America (Brucker, 2006). The manufacturer, Wyeth, stopped making the sponge rather than upgrade its manufacturing plant after the FDA found deficiencies, but the device's effectiveness and safety were never questioned. After receiving re-approval from the FDA in 2005, the contraceptive sponge is once again being marketed to women.

The contraceptive sponge is a soft polyurethane concave device that prevents pregnancy by covering the cervix and releasing spermicide. While it was less effective than several other methods and does not offer protection against STIs, the sponge achieved a wide following among women who appreciated the spontaneity with which it could be used and its easy availability. To use the sponge, the woman first wets it with water, then inserts it into the vagina with a finger, using a cord loop attachment. It can be inserted up to 24 hours before intercourse and should be left in place for at least 6 hours following intercourse. The sponge provides protection for up to 12 hours, but should not be left in for more than 30 hours after insertion to avoid the risk of toxic shock syndrome (Brucker, 2006). The sponge is a contraceptive method but does not protect against STIs.

Hormonal Methods

Several options are available to women who want long-term but not permanent protection against pregnancy. These methods of contraception work by altering the hormones within a woman's body. They rely on estrogen and progestin or progestin alone to prevent ovulation. When used consistently, these methods are a most reliable way to prevent pregnancy. Hormonal methods include oral contraceptives, injectables, implants, vaginal rings, and transdermal patches.

Oral Contraceptives

As early as 1937, scientists recognized that the injection of progesterone inhibited ovulation in rabbits and provided contraception. Breakthrough bleeding was reported in early clinical trials in women, and the role of estrogen in cycle control was launched. This established the rationale for modern combination **oral contraceptives (OCs)** that contain both estrogen and progesterone (Roederer, Blackwell & Blenning, 2006). In 1960 the FDA approved the first combination OC, Enovid-10 (150 mcg estrogen and 9 mg progesterone), for use in the United States. Today, nearly 50 combination OCs are available in the United States. The most notable change in over 40 years of OC improvement has been the lowering of the estrogen dose to as low as 20 mcg and the introduction of new progestins.

Oral contraceptives are the most popular method of nonsurgical contraception, used by approximately 18 million women in the United States (Dirubbo, 2006) (Fig. 4.12). Unlike the original OCs that women took decades ago, the new low-dose forms carry fewer health risks.

OCs, while most commonly prescribed for contraception, have long been used in the management of a wide range of conditions and have many health benefits, such as:

- Reduced incidence of ovarian and endometrial cancer
- Prevention and treatment of endometriosis
- Decreased incidence of acne and hirsutism




FIGURE 4.12 Oral contraceptive.

- Decreased incidence of ectopic pregnancy
- Decreased incidence of acute PID
- Reduced incidence of fibrocystic breast disease
- Decreased perimenopausal symptoms
- Increased menstrual cycle regularity
- Lower incidence of colorectal cancer
- Reduced iron-deficiency anemia by treating menorrhagia
- Reduced incidence of dysmenorrhea (Roederer, Blackwell & Blenning, 2006)

OCs work primarily by suppressing ovulation by adding estrogen and progesterone to a woman's body, thus mimicking pregnancy. This hormonal level stifles gonadotropin-releasing hormone (GnRH), which in turn suppresses FSH and LH and thus inhibits ovulation. Cervical mucus also thickens, which hinders sperm transport into the uterus. Implantation is inhibited by suppression of the maturation of the endometrium and alterations of uterine secretions (Trussell, 2004).

The combination pills are prescribed as monophasic pills, which deliver fixed dosages of estrogen and progestin, or as multiphasic ones. Multiphasic pills (e.g., biphasic and triphasic OCs) alter the amount of progestin and estrogen within each cycle. To maintain adequate hormonal levels for contraception and enhance compliance, OCs should be taken at the same time daily.

OCs that contain progestin only are called minipills. They are prescribed for women who cannot take estrogen. They work primarily by thickening the cervical mucus to prevent penetration of the sperm and make the endometrium unfavorable for implantation. Progestin-only pills must be taken at a certain time every 24 hours. Breakthrough bleeding and a higher risk of pregnancy have made these OCs less popular than combination OCs (Mishell et al., 2007).

Extended OC regimens have been used for the management of menstrual disorders and endometriosis for years but now are attracting wider attention. Surveys asking women about their willingness to reduce their menstrual cycles from 12 to 4 annually were returned with a resounding "yes!" (Archer, 2006). Recent studies confirm that the extended use of active OC pills carries the same safety profile as the conventional 28-day regimens (Anderson et al., 2006; Edelman et al., 2006; Grimes, 2006). The extended regimen consists of 84 consecutive days of active combination pills, followed by 7 days of placebo. The woman has four withdrawal-bleeding episodes a year. Seasonale, a combination OC, is on the market for women who choose to reduce the number of periods that they have. There is no physiologic requirement for cyclic hormonal withdrawal bleeds while taking OCs (Wysocki, 2007).

The balance between the benefits and the risks of OCs must be determined for each woman when she is being assessed for this type of contraceptive. It is a highly effective contraceptive when taken properly but can ag-

gravate many medical conditions, especially in women who smoke. Comparison Chart 4.2 lists advantages and disadvantages of OCs. A thorough history and pelvic examination, including a Pap smear, must be completed before the medication is prescribed and yearly thereafter. Women should also be counseled that the effectiveness of OCs is decreased when the woman is taking antibiotics; thus, the woman will need to use an alternative or secondary method during this period to prevent pregnancy.

Nurses need to provide OC users with a great deal of education before they leave the health care facility. They need to be able to identify early signs and symptoms that might indicate a problem.



► Take NOTE!

The mnemonic "ACHES" can help women remember the early warning signs that necessitate a return to the health care provider (Box 4.6).

Injectable Contraceptives

The **Lunelle injection** is a long-term reversible contraceptive for women. It contains the same hormones as the

COMPARISON CHART 4.2 ADVANTAGES AND DISADVANTAGES OF ORAL CONTRACEPTIVES

Advantages	Disadvantages
Regulate and shorten menstrual cycle	Offer no protection against STIs
Decrease severe cramping and bleeding	Pose slightly increased risk of breast cancer
Reduce anemia	Modest risk for vein thrombosis and pulmonary emboli
Reduce ovarian and colorectal cancer risk	Increased risk for migraine headaches
Decrease benign breast disease	Increased risk for myocardial infarction, stroke, and hypertension for women who smoke
Reduce risk of endometrial cancer	May increase risk of depression
Improve acne	User must remember to take pill daily
Minimize perimenopausal symptoms	High cost for some women
Decrease incidence of rheumatoid arthritis	
Improve PMS symptoms	
Protect against loss of bone density	

Source: Dirubbo, 2006

BOX 4.6 Early Signs of Complications for OC Users

- A: Abdominal pain may indicate liver or gallbladder problems.
- C: Chest pain or shortness of breath may indicate a pulmonary embolus.
- H: Headaches may indicate hypertension or impending stroke.
- E: Eye problems might indicate hypertension or an attack.
- S: Severe leg pain may indicate a thromboembolic event

Source: Courtney, 2006.

combination OCs. It is administered once every 28 to 33 days by intramuscular injection. It provides immediate, very effective contraception if given within 5 days after the last normal menses. Its mechanism of action, contraindications, and side effects are similar to those of OCs (Murphy, Morgan & Likis, 2006).

Depo-Provera is the trade name for an injectable form of a progesterone-only contraceptive given every 12 weeks. Depo-Provera works by suppressing ovulation and the production of FSH and LH by the pituitary gland, by increasing the viscosity of cervical mucus and causing endometrial atrophy. A single injection of 150 mg into the buttocks acts like other progestin-only products to prevent pregnancy for 3 months at a time (Fig. 4.13). The primary side effect of Depo Provera is menstrual cycle disturbance.

Recent clinical studies have raised concerns about whether Depo-Provera reduces bone mineral density. This evidence has prompted the manufacturer and the FDA to issue a warning about the long-term use of Depo-Provera and bone loss (Robinson, 2005). It is not entirely

clear if this loss in bone mineral density is reversible because there haven't been any long-term prospective studies in current and past users.

Transdermal Patches

A **transdermal patch**, Ortho Evra, is also available. It is a matchbox-sized patch containing hormones that are absorbed through the skin when placed on the lower abdomen, upper outer arm, buttocks, or upper torso (avoiding the breasts). The patch is applied weekly for 3 weeks, followed by a patch-free week during which withdrawal bleeding occurs. The patch delivers continuous levels of progesterone and estrogen. Transdermal absorption allows the drug to enter the bloodstream directly, avoiding rapid inactivation in the liver known as first-pass metabolism. Since estrogen and progesterone are metabolized by liver enzymes, avoiding first-pass metabolism was thought to reduce adverse effects. However, recent evidence suggests that the risk of venous thrombosis and embolism is increased with the patch (Courtney, 2006). Additional studies are underway to understand the clinical significance of these latest findings, but in the interim nurses need to focus on ongoing risk assessment and should be prepared to discuss current research findings with clients.

Compliance with combination contraceptive patch use has been shown to be significantly greater than compliance with OCs (Graziottin, 2006). The patch provides combination hormone therapy with a side effect profile similar to that of OCs. The manufacturer is currently evaluating extended regimens for the patch (Stewart et al., 2006) (Fig. 4.14).

Vaginal Rings

The contraceptive **vaginal ring**, NuvaRing, is a flexible, soft, transparent ring that is inserted by the user for a 3-week period of continuous use followed by a ring-free week to allow withdrawal bleeding (Fig. 4.15). The ring can be inserted by the woman and does not have to be




FIGURE 4.13 Injectable contraceptive.




FIGURE 4.14 Transdermal patch.



FIGURE 4.15 Vaginal ring.

fitted. The woman compresses the ring and inserts it into the vagina, behind the pubic bone, as far back as possible, but precise placement is not critical. The hormones are absorbed through the vaginal mucosa. It is left in place for 3 weeks and then removed and discarded. Effectiveness and adverse events are similar to those seen with combination OCs. Clients need to be counseled regarding timely insertion of the ring and what to do in case of accidental expulsion. This device is also being tested for extended regimens to reduce menstrual bleeding.

Implantable Contraceptives

The **implant** is a subdermal time-release method that delivers synthetic progestin. Once in place, it delivers several years of continuous, highly effective contraception. Like progestin-only pills, implants act by inhibiting ovulation and thickening cervical mucus so sperm cannot penetrate. A single-rod progestin implant (Implanon) received FDA approval in 2006 (Tolaymat & Kaunitz, 2007). The side effects are also similar to progestin-only pills: irregular bleeding, headaches, weight gain, breast tenderness, and depression. Fertility is restored quickly after it is removed. Implants require a minor surgical procedure for

both insertion and removal. The implants don't offer any protection against STIs.

Intrauterine Systems

Intrauterine systems are small plastic T-shaped objects that are placed inside the uterus to provide contraception (Fig. 4.16). They prevent pregnancy by making the endometrium of the uterus hostile to implantation of a fertilized ovum by causing a nonspecific inflammatory reaction (Hearton, 2006). Monthly periods become lighter, shorter, and less painful, making this a useful method for women with heavy, painful periods. Some implants may contain copper or progesterone to enhance their effectiveness. One or two attached strings protrude into the vagina so that the user can check for placement.

Currently there are three intrauterine systems available in the United States: the copper ParaGard-T-380A; Progestasert, a progesterone device; and the levonorgestrel intrauterine system (LNG-IUS) Mirena, a levonorgestrel-releasing device. The ParaGard-T-380A is approved for 10 years of use. The Progestasert may stay in place 1 year, then must be removed and replaced. Mirena provides intrauterine conception for up to 5 years. An advantage of these hormonally impregnated intrauterine systems is that they are relatively maintenance-free: users must consciously discontinue using them to become pregnant rather than making a daily decision to avoid conception (French et al., 2006). Box 4.7 highlights warning signs of complications.

Emergency Contraception

Unplanned pregnancy is a major health, economic, and social issue for women. Approximately half of all unplanned pregnancies end in abortion (CDC, 2006). **Emergency contraception (EC)** reduces the risk of pregnancy after unprotected intercourse or contraceptive failure such as condom breakage (Lever, 2005). It is used within 72 hours of unprotected intercourse to prevent pregnancy. The sooner ECs are taken, the more effective





FIGURE 4.16 (A) Intrauterine system. (B) An IUS in place in the uterus.

BOX 4.7 Warnings for Intrauterine System Users of Potential Complications

- P: Period late, pregnancy, abnormal spotting or bleeding
 A: Abdominal pain, pain with intercourse
 I: Infection exposure, abnormal vaginal discharge
 N: Not feeling well, fever, chills
 S: String length shorter or longer or missing

Source: Hatcher et al., 2004.

they are. They reduce the risk of pregnancy for a single act of unprotected sex by almost 80% (Cheng et al., 2006). The methods available in the United States are progestin-only OCs, combination OCs, EC kit (Plan B) (Fig. 4.17), or insertion of a copper-releasing intrauterine system up to 7 days after unprotected intercourse (Lever, 2005). The FDA recently approved Plan B (levonorgestrel) to be sold over the counter to women aged 18 and older; it is still available by prescription to women younger than 18 years (U.S. Food & Drug Administration, 2006). Table 4.5 lists recommended oral medication and intrauterine regimens.

Prime points to stress concerning ECs are:

- ECs do not offer any protection against STIs or future pregnancies.
- ECs should not be used in place of regular birth control, as they are less effective.
- ECs are regular birth control pills given at higher doses and more frequently.
- ECs are contraindicated during pregnancy because they are considered to be teratogenic (Ravin, 2006).



FIGURE 4.17 Emergency contraceptive kit.

Contrary to popular belief, ECs do not induce abortion and are not related to mifepristone or RU-486, the so-called abortion pill approved by the FDA in 2000. Mifepristone chemically induces abortion by blocking the body's progesterone receptors, which are necessary for pregnancy maintenance. ECs simply prevent embryo creation and uterine implantation from occurring in the first place. There is no evidence that ECs have any effect on an already-implanted ovum. The side effects are nausea and vomiting.

Sterilization

Sterilization is an attractive method of contraception for those who are certain they do not want any, or any more, children. **Sterilization** refers to surgical procedures intended to render the person infertile. It is one of the most popular methods of contraception in the United States and worldwide (Swica & Westhoff, 2006). More women than men undergo surgical sterilization. According to the

TABLE 4.5 EMERGENCY CONTRACEPTION (EC) OPTIONS

Product	First Dose (Within 72 Hours)	Second Dose (Taken 12 Hours Later)
Combined OCs		
Preven	2 tablets	2 tablets
Ovral		
Lo/Ovral, Nordette	4 tablets	4 tablets
Levlen, TriLevlen		
Triphasil		
Progestin-Only OCs		
Ovrette	20 tablets	20 tablets
Plan B	1 tablet	1 tablet
Intrauterine Devices		
Copper-containing IUD such as Paragard- T-380A	Inserted within 7 days after unprotected sexual episode	Can be left in for long-term contraception




FIGURE 4.18 Laparoscopy for tubal sterilization.

CDC, approximately 18% of women undergo female sterilization in comparison to 7% of men in the United States (CDC, 2006). Sterilization should be considered a permanent end to fertility because reversal surgery is difficult, expensive, and not highly successful.

Tubal Ligation

Tubal ligation, the sterilization procedure for women, can be performed postpartum, after an abortion, or as an interval procedure unrelated to pregnancy. A laparoscope is inserted through a small subumbilical incision to provide a view of the fallopian tubes. They are grasped and sealed with a cauterizing instrument or with rings, bands, or clips or cut and tied (Fig. 4.18).

A new approach used to visualize the fallopian tubes is through the cervix instead of the abdominal incision. This procedure, called transcervical sterilization, offers several advantages over conventional tubal ligation: general anesthesia and incisions are not needed, thereby increasing safety, lowering costs, and improving access to sterilization. A tiny coil (Essure) is introduced and released into the fallopian tubes through the cervix. The coil promotes tissue growth in the fallopian tubes, and over a period of 3 months, this growth blocks the tubes (Valle, 2006). This less-invasive technique has become increasingly popular.

Vasectomy

Male sterilization is accomplished with a surgical procedure known as a **vasectomy**. It is usually performed under local anesthesia in an urologist's office, and most men can return to work and normal activities in a day or two. The procedure involves making a small incision into the scrotum and cutting the vas deferens, which carries sperm from the testes to the penis (Fig. 4.19). After vasectomy, semen no longer contains sperm. This is not immediate, though, and the man must submit semen specimens for analysis until two specimens show that no sperm is present. When the specimen shows azoospermia, the man's sterility is then confirmed (Dassow & Bennett, 2006).

Nursing Management of the Woman Choosing a Contraceptive Method

The choice of a contraceptive method is a very personal one involving many factors. What makes a woman choose one contraceptive method over another? In making contraceptive choices, couples must balance their sexual




FIGURE 4.19 Vasectomy. (A) Site of vasectomy incisions. (B) The vas deferens is cut with surgical scissors. (C) Cut ends of the vas deferens are cauterized to ensure blockage of the passage of sperm. (D) Final skin suture.

lives, their reproductive goals, and each partner's health and safety. The search for a choice that satisfies all three objectives is challenging. A method that works for a sexually active teenage girl may not meet her needs later in life. Several considerations influence a person's choice of contraceptives:

- Motivation
- Cost
- Cultural and religious beliefs (Box 4.8)
- Convenience
- Effectiveness
- Side effects
- Desire for children in the future
- Safety of the method
- Comfort level with sexuality
- Protection from STIs
- Interference with spontaneity

If a contraceptive is to be effective, the woman must understand how it works, must be able to use it correctly and consistently, and must be comfortable and confident with it. If a patient cannot comply with taking a pill daily, consider a method used once a week (transdermal patches), once every 3 weeks (transvaginal ring), or once every 3 months (Depo-Provera injection). Another option may be a progesterone intrauterine device that lasts 3 to 5 years and reduces menstrual flow significantly.

Regardless of which method is chosen, the client's needs should be paramount in the discussion. The nurse can educate clients about which methods are available and their advantages and disadvantages, efficacy, cost, and safety. Counseling can help the woman choose a contra-

ceptive method that is efficacious and fits her preferences and lifestyle.

Nursing Assessment

When assessing which contraceptive method might meet the client's needs, the nurse might ask:

- Do your religious beliefs interfere with any methods?
- Will this method interfere with your sexual pleasure?
- Are you aware of the various methods currently available?
- Is cost a major consideration, or does your insurance cover it?
- Does your partner influence which method you choose?
- Have you heard anything troubling about any of the methods?
- How comfortable are you touching your own body?
- What are your future plans for having children?

Although deciding on a contraceptive is a very personal decision between a woman and her partner, nurses can assist in this process by performing a complete health history and physical examination, and by educating the woman and her partner about necessary laboratory and diagnostic testing. Areas of focus during the nursing assessment are as follows:

- Medical history: smoking status, cancer of reproductive tract, diabetes mellitus, migraines, hypertension, thromboembolic disorder, allergies, risk factors for cardiovascular disease
- Family history: cancer, cardiovascular disease, hypertension, stroke, diabetes
- OB/GYN history: menstrual disorders, current contraceptive, previous STIs, PID, vaginitis, sexual activity
- Personal history: use of tampons and female hygiene products, plans for childbearing, comfort with touching herself, number of sexual partners and their involvement in the decision
- Physical examination: height, weight, blood pressure, breast examination, thyroid palpation, pelvic examination
- Diagnostic testing: urinalysis, complete blood count, Pap smear, wet mount to check for STIs, HIV/AIDS tests, lipid profile, glucose level

Figure 4.20 shows an example of a family planning flow record that can be used during the assessment. After collecting the assessment data above, consider the medical factors to help decide if she is a candidate for all methods or whether some should be eliminated. For example, if she reports she has multiple sex partners and has a lengthy history of various pelvic infections, she would not be a good candidate for an intrauterine system, based on her infection history. Barrier methods (male or female

BOX 4.8 Selected Religious Choices for Family Planning and Abortion

- Roman Catholic—Abstinence and natural family planning; no abortion
- Judaism—Yes for family planning and abortion in first trimester
- Islam—Family planning accepted; abortion only for serious reasons
- Protestant Christianity—Firmly in favor of family planning; mixed on abortion
- Buddhism—Long experience with family planning and abortion
- Hinduism—Accept both family planning and abortion
- Native American religions—Accept both family planning and abortion
- Chinese religions—Taoism and Confucianism accept both

Source: Maguire, 2004.

FAMILY PLANNING FLOW (VISIT) RECORD				Name: _____	
				ID #: _____	
				Date of Birth: _____	
		Date: _____		Date: _____	
Current Method					
Reason for Visit					
LMP					
SUBJECTIVE DATA		Pt.	Comments	Pt.	Comments
Severe headaches					
Depression					
Visual abnormalities					
Dyspnea/chest pain					
Breast changes					
SBE					
Abdominal pain					
Nausea and vomiting					
Dysuria/frequency					
Menstrual irregularities					
Vaginal discharge/infections					
Leg pain					
Surgery, injury, infections, or serious illness since last visit					
Allergic reaction					
Pregnancy plans					
Other					
OBJECTIVE DATA		Weight	B.P.	Weight	B.P.
Other					
Lab					
ASSESSMENT					
Check here if assessment continues on progress notes		O		O	
PLAN					
Type of contraceptive given					
COUNSELING/EDUCATION					
Next appointment					
SIGNATURE/TITLE					
SIGNATURE/TITLE					
O = normal ✓ = abnormal					

FIGURE 4.20 Family planning flow (visit) record.

condoms) of contraception might be recommended to this client to offer protection against STIs.

Nursing Diagnoses

A few nursing diagnoses that might be appropriate based on the nurse's assessment during the decision-making process include:

- Deficient knowledge related to:
 - Methods available
 - Side effects/safety
 - Correct use of method chosen
 - Previous myths believed
- Risk for infection related to:
 - Unprotected sexual intercourse
 - Past history of STIs
 - Methods offering protection

Nursing diagnoses applicable to the contraceptive would be:

- Health-seeking behaviors related to:
 - Perceived need for limiting number of children
 - Overall health relative to contraceptives
- Risk for ineffective health maintenance related to:
 - Not being familiar with the various contraceptive methods
 - Being unaware of high-risk sexual behavior leading to STIs
- Fear related to:
 - Not understanding the correct procedure to use
 - Unintended pregnancy occurring if not used correctly
 - General health concerning the long-term side effects

Nursing Interventions

Contraception is an important issue for all couples, and the method used should be decided by the woman and her partner jointly. Facilitate this process by establishing a trusting relationship with the client and by providing unbiased, accurate information about all methods available. As a nurse, reflect honestly on your feelings towards contraceptives while allowing the client's feelings to be central. Be aware of the practical issues involved in contraceptive use, and avoid making assumptions, making decisions on the woman's behalf, and making judgments about her and her situation. To do so, it is important to keep up to date on the latest methods available and convey this information to clients. Encourage female clients to take control of their lives by sharing information that allows them to plan their futures.

The following guidelines are helpful in counseling and educating the client or couple about contraceptives:

- Encourage the client/couple to participate in choosing a method.
- Provide client education. The client/couple must be informed users before the method is agreed upon. Education should be targeted to the client's level so it

is understood. Provide step-by-step teaching and an opportunity for practice for certain methods (cervical caps, diaphragms, vaginal rings, and condoms). See Teaching Guidelines 4.5 and Figure 4.21.


- Obtain written informed consents, which are needed for intrauterine systems, implants, abortion, or sterilization. Informed consent implies that the client is making a knowledgeable, voluntary choice; has received complete information about the method, including the risks; and is free to change her mind before using the method or having the procedure (Youngkin & Davis, 2004).
- Discuss contraindications for all selected contraceptives.
- Consider the client's cultural and religious beliefs when providing care.
- Address myths and misperceptions about the methods under consideration in your initial discussion of contraceptives.

It is also important to clear up common misconceptions about contraception and pregnancy. Clearing up misconceptions will permit new learning to take hold and a better client response to whichever methods are explored and ultimately selected. Some common misconceptions include:

- Breastfeeding protects against pregnancy.
- Pregnancy can be avoided if the male partner "pulls out" before he ejaculates.
- Pregnancy can't occur during menses.
- Douching after sex will prevent pregnancy.
- Pregnancy won't happen during the first sexual experience.
- Taking birth control pills protects against STIs.
- The woman is too old to get pregnant.
- Irregular menstruation prevents pregnancy.

When discussing in detail each method of birth control, focus on specific information for each method outlined. Include information such as how this particular method works to prevent pregnancy under normal circumstances of use; the noncontraceptive benefits to overall health; advantages and disadvantages of all methods; the cost involved for each particular method; danger signs that need to be reported to the health care provider; and the required frequency of office visits needed for the particular method.

In addition, outline factors that place the client at risk for method failure. There are several reasons why there are contraceptive failures. Use Table 4.6 to provide patient education concerning a few of the reasons for contraceptive failure. Help clients who have chosen abstinence or fertility awareness methods to define the sexual activities in which they want and don't want to participate. This helps them set sexual limits or boundaries. Help them to develop communication and negotiation skills that will allow them to be successful. Supporting, encouraging, and respecting a couple's choice of abstinence is vital for nurses.



TEACHING GUIDELINES 4.5

Tips for Cervical Caps, Diaphragms, Vaginal Rings, and Condoms

Cervical Cap Insertion/Removal Technique

- It is important to be involved in the fitting process.
- To insert the cap, pinch the sides together, compress the cap dome, insert into the vagina, and place over the cervix.
- Use one finger to feel around the entire circumference to make sure there are no gaps between the cap rim and the cervix.
- After a minute or two, pinch the dome and tug gently to check for evidence of suction. The cap should resist the tug and not slide off easily.
- To remove the cap, press the index finger against the rim and tip the cap slightly to break the suction, and gently pull out the cap.
- The woman should practice inserting and removing the cervical cap three times to validate her proficiency with this device.

Client teaching and counseling regarding the cervical cap

- Fill the dome of the cap up about one-third full with spermicide cream or jelly. Do not apply spermicide to the rim, since it may interfere with the seal.
- Wait approximately 30 minutes after insertion before engaging in sexual intercourse to be sure that a seal has formed between the rim and the cervix.
- Leave the cervical cap in place for a minimum of 6 hours after sexual intercourse. It can be left in place for up to 48 hours without additional spermicide being added.
- Do not use during menses due to the potential for toxic shock syndrome. Use an alternative method such as condoms during this time.
- Inspect the cervical cap prior to insertion for cracks, holes, or tears.
- After using the cervical cap, wash it with soap and water, dry thoroughly, and store in its container.

Diaphragm Insertion/Removal Technique

- Always empty the bladder prior to inserting the diaphragm.
- Inspect diaphragm for holes or tears by holding it up to a light source, or fill it with water and check for a leak.
- Place approximately a tablespoon of spermicidal jelly or cream in the dome and around the rim of the diaphragm.
- The diaphragm can be inserted up to 6 hours prior to intercourse.

- Select the position that is most comfortable for insertion:
 - Squatting
 - Leg up, raising the nondominant leg up on a low stool
 - Reclining position, lying on her back in bed
 - Sitting forward on the edge of a chair
- Hold the diaphragm between the thumb and fingers and compress it to form a “figure-eight” shape.
- Insert the diaphragm into the vagina, directing it downward as far as it will go.
- Tuck the front rim of the diaphragm behind the pubic bone so that the rubber hugs the front wall of the vagina.
- Feel for the cervix through the diaphragm to make sure it is properly placed.
- To remove the diaphragm, insert the finger up and over the top side and move slightly to the side, breaking the suction.
- Pull the diaphragm down and out of the vagina.


Client Teaching and Counseling Regarding the Diaphragm

- Avoid the use of oil-based products such as baby oil, since this may weaken the rubber.
- Wash the diaphragm with soap and water after use and dry thoroughly.
- Place the diaphragm back into the storage case.
- The diaphragm may need to be refitted after weight loss or gain or childbirth.
- Diaphragms should not be used by women with latex allergies.

Vaginal Ring Insertion/Removal Technique and Counseling

- Each ring is used for one menstrual cycle, which consists of 3 weeks of continuous use followed by a ring-free week to allow for menses.
- No fitting is necessary—one size fits all.
- The ring is compressed and inserted into the vagina, behind the pubic bone, as far back as possible.
- Precision placement is not essential.
- Backup contraception is needed for 7 days if the ring is expelled for more than 3 hours during the 3-week period of continuous use.
- The vaginal ring is left in place for 3 weeks, then removed and discarded.
- The vaginal ring is not recommended for women with uterine prolapse or lack of vaginal muscle tone (Youngkin & Davis, 2004).

(continued)



TEACHING GUIDELINES 4.5

Tips for Cervical Caps, Diaphragms, Vaginal Rings, and Condoms (continued)

Male Condom Insertion/Removal Technique and Counseling

- Always keep the condom in its original package until ready to use.
- Store in a cool, dry place.
- Spermicidal condoms should be used if available.
- Check expiration date before using.
- Use a new condom for each sexual act.
- Condom is placed over the erect penis prior to insertion.
- Place condom on the head of the penis and unroll it down the shaft.
- Leave a half-inch of empty space at the end to collect ejaculate.
- Avoid use of oil-based products, because they may cause breakage.
- After intercourse, remove the condom while the penis is still erect.
- Discard condom after use.

Female Condom Insertion/Removal Technique and Counseling

- Practice wearing and inserting prior to first use with sexual intercourse.
- Condom can be inserted up to 8 hours before intercourse.
- Condom is intended for one-time use.
- It can be purchased over the counter—one size fits all.
- Avoid wearing rings to prevent tears; long fingernails can also cause tears.
- Spermicidal lubricant can be used if desired.
- Insert the inner ring high in the vagina, against the cervix.
- Place the outer ring on the outside of the vagina.
- Make sure the erect penis is placed inside the female condom.
- Remove the condom after intercourse. Avoid spilling the ejaculate.

After clients have chosen a method of contraception, it is important to address the following:

- Emphasize that a second method to use as a backup is always needed.
- Provide both oral and written instructions on the method chosen.
- Discuss the need for STI protection if not using a barrier method.
- Inform the client about the availability of ECs.



FIGURE 4.21 The nurse demonstrates insertion of a vaginal ring during client teaching.

Abortion

Abortion is defined as the expulsion of an embryo or fetus before it is viable (Alexander et al., 2007). Abortion can be a medical or surgical procedure. The purpose of abortion is to terminate a pregnancy. Surgical abortion is the most common procedure performed in the United States (approximately 1.6 million annually) and might be the most common surgical procedure in the world (Speroff & Fritz, 2005). Both medical and surgical abortions are safe and legal in the United States; an abortion is considered a woman's constitutional right based on the fundamental right to privacy (Curlin et al., 2007).

Since the landmark U.S. Supreme Court decision *Roe v. Wade* legalized abortion in 1973, debate has continued over how and when abortions are provided. Every state has laws regulating some aspects of the provision of abortion, and many have passed restrictions such as parental consent or notification requirements, mandated counseling and waiting periods, and limits on funding for abortion. Each state addresses these matters independently, and the laws that are passed or enforced are a legislative decision and a function of the political system. Although opponents of abortion continue to be very much a part of the current debates, recently they have refocused their attention on “regulation legislation” to reduce the number of abortions not medically necessary.

TABLE 4.6 CONTRACEPTIVE PROBLEMS AND EDUCATIONAL NEEDS

Contraceptive Failure Problem	Client Education Needed
Not following instructions for use of contraceptive correctly	Take pill the same time every day. Use condoms properly and check condition before using. Make sure diaphragm or cervical cap covers cervix completely. Check IUD for placement monthly.
Inconsistent use of contraceptive	Contraceptives must be used regularly to achieve maximum effectiveness. All it takes is one unprotected act of sexual intercourse to become pregnant. 2% to 5% of condoms will break or tear during use.
Condom broke during sex	Check expiration date. Store condoms properly. Use only a water-based lubricant. Watch for tears caused by long fingernails. Use spermicides to decrease possibility of pregnancy if failure occurs.
Use of antibiotics or other herbs taken with OCs	Use alternative methods during the antibiotic therapy, plus 7 additional days. Implement on day 1 of taking antibiotics.
Belief that you can't get pregnant during menses or that it is safe "just this one time"	It may be possible to become pregnant on almost any day of the menstrual cycle.

Surgical Abortion

Surgical abortion is usually carried out by vacuum aspiration or suction curettage. It is an ambulatory procedure done under local anesthesia. The cervix is dilated prior to surgery and then the products of conception are removed by suction evacuation. The uterus may gently be scraped by curettage to make sure that it is empty. The entire procedure lasts about 10 minutes.

HEALTHY PEOPLE 2010	
Objective	Significance
Reduce pregnancies among adolescent females. Increase the proportion of sexually active, unmarried adolescents age 15–17 years who use contraception that both effectively prevents pregnancy and provides barrier protection against disease.	Would reduce number of unplanned pregnancies and girls not finishing their education. This would in turn reduce the number of single parents on state financial assistance.
Increase the proportion of young adults who have received formal instruction before turning age 18 years on reproductive health issues, including all of the following topics: birth control methods, safer sex to prevent HIV, prevention of sexually transmitted disease, and abstinence.	Awareness of contraceptive methods brings about better compliance and prevention of unintended pregnancies in this age group.
Reduce AIDS and the number of HIV infections among adolescents and adults.	Reduce the number of HIV/AIDS victims by using barrier methods to prevent the transmission of this fatal STI.
Reduce the proportion of adolescents and young adults with <i>Chlamydia trachomatis</i> infections.	Reduce the number of women with infertility issues secondary to <i>Chlamydia</i> infections.

Medical Abortion

In a medical abortion, the woman takes certain medications to induce a miscarriage to remove the products of conception. There are two methods currently used to terminate a pregnancy during the first trimester. The first method uses methotrexate (an antineoplastic agent) followed by misoprostol (a prostaglandin agent) given as a vaginal suppository or in oral form 3 to 7 days later. Methotrexate induces abortion because of its toxicity to trophoblastic tissue, the growing embryo. Misoprostol works by causing uterine contractions, which helps to expel the products of conception. This method is 90% to 98% successful in completing an abortion (Hatcher et al., 2004).

The second method used to induce first-trimester abortions involves using mifepristone (a progesterone antagonist) followed 48 hours later by misoprostol (a prostaglandin agent), which causes contractions of the uterus and expulsion of the uterine contents. Mifepristone, the generic name for RU-486, is sold under the brand names Mifeprex and Early Option. Mifepristone is

a potent oral anti-progestogen; it blocks the action of progesterone that prepares the endometrium for implantation and then maintains the pregnancy. This method is 95% effective when used within 49 days after the last menstrual cycle (Hatcher et al., 2004).

Abortion is a very emotional, deeply personal issue. Give support and accurate information. If for personal, religious, or ethical reasons you feel unable to actively participate in the care of a woman undergoing an abortion, you still have the professional responsibility to ensure that the woman receives the nursing care and help she requires. This may necessitate a transfer to another area or a staffing reassignment.

Menopause

The change of life. The end of fertility. The beginning of freedom. Whatever people call it, menopause is a unique and personal experience for every woman. **Menopause** refers to the cessation of regular menstrual cycles. It is the end of menstruation and childbearing capacity. The average age of natural menopause—defined as 1 year without a menstrual period—is 51 years old (Alexander et al., 2007). With current female life expectancy at 80, this event comes in the middle of a woman's adult life.



► Take NOTE!

Humans are virtually the only species to outlive their reproductive capacities.

Menopause signals the end of an era for many women. It concludes their ability to reproduce, and some women find advancing age, altered roles, and these physiologic changes to be overwhelming events that may precipitate depression and anxiety (Kessenich, 2007). Menopause does not happen in isolation. Midlife is often experienced as a time of change and reflection. Change happens in many arenas: children are leaving or returning home, employment pressures intensify as career moves or decisions are required, elderly parents require more care or the death of a parent may have a major impact, and partners are retrenching or undergoing their own midlife crises. Women must negotiate all these changes in addition to menopause. Managing these stressful changes can be very challenging for many women as they make the transition into midlife.

A woman is born with approximately 500,000 ova, but only 300 to 400 ever mature fully to be released during the menstrual cycle. The absolute number of ova in the ovary is a major determinant of fertility. Over the course of her premenopausal life there is a steady decline in the number of immature ova. No one understands this depletion, but it does not occur in isolation. Maturing

ova are surrounded by follicles that produce two major hormones: estrogen, in the form of estradiol, and progesterone. The cyclic maturation of the ovum is directed by the hypothalamus. The hypothalamus triggers a cascade of neurohormones, which act through the pituitary and the ovaries as a pulse generator for reproduction.

This hypothalamic-pituitary-ovarian axis begins to break down long before there is any sign that menopause is imminent. Some scientists believe that the pulse generator in the hypothalamus simply degenerates; others speculate that the ovary becomes more resistant to the pituitary hormone FSH and simply shuts down (Krantz, 2007b). The final act in this well-orchestrated process is amenorrhea.

As menopause approaches, more and more of the menstrual cycles become anovulatory. This period of time, usually 2 to 8 years before cessation of menstruation, is termed perimenopause (Manson, 2006). In perimenopause, the ovary begins to sputter, producing irregular and missed periods and an occasional hot flash. When menopause finally appears, viable ova are gone. Estrogen levels plummet by 90%, and estrone, produced in fat cells, replaces estradiol as the body's main form of estrogen. The major hormone produced by the ovaries during the reproductive years is estradiol; the estrogen found in postmenopausal women is estrone. Estradiol is much more biologically active than estrone (Krantz, 2007). In addition, testosterone levels decrease with menopause.

Menopause, with its dramatic decline in estrogen, affects not only the reproductive organs, but also other body systems:

- **Brain:** hot flashes, disturbed sleep, mood and memory problems
- **Cardiovascular:** lower levels of high-density lipoprotein (HDL) and increased risk of cardiovascular disease
- **Skeletal:** rapid loss of bone density increases the risk of osteoporosis
- **Breasts:** duct and glandular tissues are replaced by fat
- **Genitourinary:** vaginal dryness, stress incontinence, cystitis
- **Gastrointestinal:** less calcium is absorbed from food, increasing the risk for fractures
- **Integumentary:** skin becomes dry and thin, and collagen levels decrease
- **Body shape:** more abdominal fat; waist size swells relative to hips

Therapeutic Management

Menopause should be managed individually. In the past, despite the wide diversity of symptoms and risks, the traditional reaction was to reach for the one-size-fits-all therapy: hormone therapy. Today the medical community is changing its thinking in light of the Women's Health Initiative (WHI) study and the Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II), which reported

that long-term hormone therapy (HT) increased the risks of heart attacks, strokes, and breast cancer; in short, the overall health risks of HT exceeded the benefits (Writing Group, 2002, p. 321). In addition, HT didn't protect against the development of coronary artery disease, nor did it prevent the progression of coronary artery disease, as it was previously touted to do (Shelby & O'Hair, 2007). As expected, the fallout from this study and others forced practitioners to re-evaluate their usual therapies and tailor treatment to each client's history, needs, and risk factors.

There is a universe of treatment options out there, but factors in the client's history should be the driving force when determining therapy. Women need to educate themselves about the latest research findings and collaborate with their health care provider on the right menopause therapy. The following factors should be considered in management:

- HT is not indicated to treat or prevent cardiovascular disease, according to WHI. Instead, consider lipid-lowering agents and lifestyle changes if risk or disease is present.
- HT should not be taken for more than 5 years for vasomotor symptoms. Use the lowest dose possible for any hormone therapy.
- HT is acceptable as long as there is a clear indication for use, the woman is under medical supervision, and she is aware of the risks and benefits (North American Menopause Society, 2004).
- Consider nonhormonal therapies such as bisphosphonates and selective estrogen receptor modulators (SERMs).
- Consider weight-bearing exercises, calcium, vitamin D, smoking cessation, and avoidance of alcohol to treat or prevent osteoporosis.
- Annual breast examinations and mammograms are essential.
- Local estrogen creams can be used for vaginal atrophy.
- Consider herbal therapies for symptoms (Krantz, 2007).

Although numerous symptoms have been attributed to menopause (Box 4.9), some of them are more closely related to the aging process than to estrogen deficiency. A few of the more common menopausal conditions and their management will be discussed.

Managing Hot Flashes and Night Sweats

Hot flashes and night sweats are classic signs of estrogen deficiency and the predominant complaint of perimenopausal women. A hot flash is a transient and sudden sensation of warmth that spreads over the body, particularly the neck, face, and chest. Hot flashes are caused by vasomotor instability. Nearly 85% of menopausal women experience them (Alexander et al., 2007). Hot flashes are an early and acute sign of estrogen deficiency. These flashes

BOX 4.9 Common Symptoms of Menopause

- Hot flashes or flushes of the head and neck
- Dryness in the eyes and vagina
- Personality changes
- Anxiety and/or depression
- Loss of libido
- Weight gain and water retention
- Night sweats
- Fatigue
- Irritability
- Insomnia
- Stress incontinence
- Heart palpitations

Source: Chedraui et al., 2007.

can be mild or extreme and can last from 2 to 30 minutes (Grady, 2006).

There are many options for treating hot flashes. Treatment must be based on symptom severity, the client's medical history, and the client's values and concerns. Although the gold standard in the treatment of hot flashes is estrogen, this is not recommended for all women. The following are suggestions for the management of hot flashes:

- Pharmacologic options
 - HT unless contraindicated
 - Androgen therapy (potentiates estrogen)
 - Estrogen and androgen combinations
 - Progestin therapy (Depo-Provera injection every 3 months)
 - Clonidine (central alpha-adrenergic agonist) weekly patch
 - Neurontin (anti-seizure) decreased hot flashes
 - Acupuncture reduced frequency of hot flashes
 - Propranolol (beta-adrenergic blocker)
 - Gabapentin (Neurontin): antiseizure drug
 - SSRIs: venlafaxine (Effexor) and sertraline (Zoloft) have shown promise
 - Vitamin E: 100 mg daily (Rubin, 2007)
- Lifestyle changes
 - Lower room temperature; use fans.
 - Wear clothing in layers for easy removal.
 - Limit caffeine and alcohol intake.
 - Drink 8 to 10 glasses of water daily.
 - Stop smoking or cut back.
 - Avoid hot drinks and spicy food.
 - Take calcium (1,200 to 1,500 mg) and vitamin D (400 to 600 IU).
 - Try relaxation techniques, deep breathing, and meditation.
 - Exercise daily, but not just before bedtime.

- Maintain a healthy weight.
- Identify stressors and learn to manage them.
- Keep a diary to identify triggers of hot flashes.
- Alternative therapies
 - Phytoestrogens: isoflavones, ligands, coumenstrols
 - Black cohosh
 - Chamomile: mild sedative to alleviate insomnia
 - Unopposed transdermal progesterone
 - Compounded bioidentical hormones
 - Estrogen
 - Progesterone
 - Testosterone
 - Dehydroepiandrosterone (DHEA)
 - Pregnenolone (Campbell, 2006)
 - Chasteberry (vitex): balances progesterone and estrogen
 - Dong quai: acts as a form of phytoestrogen
 - Ginseng: purported to improve memory
 - St. John's wort: reduces depression and fatigue
 - Valerian root: induces sleep and relaxation (AAFP, 2006)

Many women are choosing alternative treatments for managing menopausal symptoms. Because of their natural origin, women perceive that alternative treatments are safer. The interest in phytoestrogens came about because of the low prevalence of hot flashes in Asian women, which was attributed to their diet being rich in phytoestrogens (Manson, 2006). Recent studies have found that black cohosh, multibotanical herbs, and increased soy intake do not reduce the frequency or severity of menopausal hot flashes or night sweats (ACOG, 2005; Huntzinger, 2006; Newton et al., 2006; Seppa, 2007). Other remedies for easing menopausal symptoms might include red clover, motherwort, ginseng, sarsaparilla root, valerian root, L-tryptophan, calcium-magnesium, and kelp tablets (Haas, 2007). Again, research thus far has been skeptical about their efficacy, but many women report they ease their symptoms and their use has skyrocketed. While there might be some benefits to their use, evidence of the efficacy of alternative products in menopause is largely anecdotal. Small, preliminary clinical trials might demonstrate the safety of some of the nonpharmacologic products. Nurses should be aware of the purported action of these agents as well as any adverse effects or drug interactions.

Managing Urogenital Changes

Menopause can be a physically and emotionally challenging time for women. In addition to the psychological burden of leaving behind the reproductive phase of life and the stigma of an “aging” body, sexual difficulties due to urogenital changes plague most women but are frequently not addressed.

Vaginal atrophy occurs during menopause because of declining estrogen levels. These changes include thinning of the vaginal walls, an increase in pH, irritation, increased

susceptibility to infection, dyspareunia, loss of lubrication with intercourse, vaginal dryness, and a decrease in sexual desire related to these changes. Decreased estrogen levels can also influence a woman's sexual function as well. Delayed clitoral reaction, decreased vaginal lubrication, diminished circulatory response during sexual stimulation, and reduced contractions during orgasm have all been linked to low estrogen levels (McKinney, 2007).

Management of these changes might include the use of estrogen vaginal tablets (Vagifem) or Premarin cream; Estring, an estrogen-releasing vaginal ring that lasts for 3 months; testosterone patches; and over-the-counter moisturizers and lubricants (Astroglide). A positive outlook on sexuality and a supportive partner are also needed to make the sexual experience enjoyable and fulfilling.



► Take NOTE!

Sexual health is an important aspect of the human experience. By keeping an open mind, listening to women, and providing evidence-based treatment options, the nurse can help improve quality of life for menopausal women.

Preventing and Managing Osteoporosis

Women are greatly affected by osteoporosis after menopause. Osteoporosis is a condition in which bone mass declines to such an extent that fractures occur with minimal trauma. Bone loss begins in the third or fourth decade of a woman's life and accelerates rapidly after menopause. It affects 8 million women, with millions more at high risk for developing it. This translates to 1 in 2 women over the age of 50 having an osteoporosis-related fracture in their lifetime (Alexander et al., 2007). This condition puts many women into long-term care, with a resulting loss of independence. Figure 4.22 shows the skeletal changes associated with osteoporosis.

Most women with osteoporosis don't know they have the disease until they sustain a fracture, usually of the wrist or hip. Risk factors include:

- Increasing age
- Postmenopausal status without hormone replacement
- Small frame, thin-boned
- Caucasian or Asian
- Impaired eyesight
- Rheumatoid arthritis
- Family history of osteoporosis
- Sedentary lifestyle
- History of treatment with:
 - Antacids with aluminum
 - Heparin
 - Steroids
 - Thyroid replacement drugs



FIGURE 4.22 Skeletal changes associated with osteoporosis. (John Radcliffe Hospital/Photo Researcher Inc.)

- Smoking and consuming alcohol
- Low calcium and vitamin D intake
- Excessive amounts of caffeine
- Anorexia nervosa or bulimia (Hansberger, 2007)

Screening tests to measure bone density are not good predictors for young women who might be at risk for developing this condition. Dual-energy x-ray absorptiometry (DXA or DEXA) is a screening test that calculates the mineral content of the bone at the spine and hip. It is highly accurate, fast, and relatively inexpensive (McNally, Kenny & Smith, 2007).

The best management for this painful, crippling, and potentially fatal disease is prevention. Women can modify many risk factors by doing the following:

- Engage in daily weight-bearing exercise, such as walking.
- Increasing calcium and vitamin D intake.
- Avoid smoking and excessive alcohol.
- Discuss your bone health with your health care provider.
- When appropriate, have a bone density test and take medication if needed (National Osteoporosis Foundation, 2007).

Medications that can help in preventing and managing osteoporosis include:

- HT (Premarin)
- SERMs (Evista)
- Calcium and vitamin D supplements (Tums)
- Bisphosphonates (Actonel or Fosamax)
- Calcitonin (Miacalcin) (Hansberger, 2007)

Preventing and Managing Cardiovascular Disease

Although cardiovascular disease is still thought of as a “man’s disease,” it is the major killer of postmenopausal women 50 to 75 years of age (Rosano et al., 2007). Half a million women die annually in the United States of cardiovascular disease, with strokes accounting for about 20% of the deaths (Alexander et al., 2007). This translates into approximately one death every minute. Coronary heart disease accounts for the majority of cardiovascular deaths in women, with nearly two thirds of these women dying suddenly without any previously recognized symptoms (Hackley, Kriebs & Rousseau, 2007).

For the first half of a woman’s life, estrogen seems to be a protective substance for the cardiovascular system by smoothing, relaxing, and dilating blood vessels. It even helps boost HDL and lower LDL levels, helping to keep the arteries clean from plaque accumulation. But when estrogen levels plummet as women age and experience menopause, the incidence of cardiovascular disease increases dramatically.

Menopause is not the only factor that increases a woman’s risk for cardiovascular disease. Lifestyle and medical history factors such as the following play a major role:

- Smoking
- Obesity
- High-fat diet
- Sedentary lifestyle
- High cholesterol levels
- Family history of cardiovascular disease
- Hypertension
- Apple-shaped body
- Diabetes

Two of the major risk factors for coronary heart disease are hypertension and dyslipidemia. Both are modifiable and can be prevented by lifestyle changes and, if needed, controlled by medication. This is why prevention is essential. In addition, women who experience early menopause lose the protection afforded by endogenous estrogen to the cardiac system and are at greater risk for more extensive atherosclerosis. Major preventive strategies include a healthy diet, increased activity, exercise, smoking cessation, decreased alcohol intake, and weight reduction.

Raising awareness of heart disease in women is an essential role for nurses. Lifestyle interventions are effective in preventing cardiovascular disease in all individuals regardless of their underlying risk (Hackley, Kriebs & Rousseau, 2007). Stressing the importance of lifestyle modifications must begin early in life and should be reinforced from the beginning of a young woman’s reproductive years through menopause. Nurses are in an ideal position to teach the importance of good nutrition, healthy weight, and daily exercise before cardiovascular disease becomes clinically evident.

Nursing Assessment

Menopause is a universal and irreversible part of the overall aging process involving a woman's reproductive system. While not a disease state, menopause does place women at greater risk for the development of many conditions of aging. Nurses can help the woman become aware of her risk for postmenopausal diseases, as well as strategies to prevent them. The nurse can be instrumental in assessing risk factors and planning interventions in collaboration with the client. These might include:

- Screening for osteoporosis, cardiovascular disease, and cancer risk
 - Assessment of blood pressure to identify hypertension
 - Blood cholesterol to identify hyperlipidemia risk
 - Mammogram to find a cancerous lesion
 - Pap smear to identify cervical cancer
 - Pelvic examination to identify endometrial cancer or masses
 - Digital rectal examination to assess for colon cancer
 - Bone density testing as a baseline at menopause to identify osteopenia (low bone mass), which might lead to osteoporosis
- Assessing lifestyle to plan strategies to prevent chronic conditions:
 - Dietary intake of fat, cholesterol, and sodium
 - Weight management
 - Calcium intake
 - Use of tobacco, alcohol, and caffeine
 - Performance of breast self-examinations

Nursing Management

There is no “magic bullet” in managing menopause. Nurses can counsel women about their risks and help them to prevent disease and debilitating conditions with specific health-maintenance education. Women should make their own decisions, but the nurse should make sure they are armed with the facts to do so intelligently. Nurses can offer a thorough explanation of the menopausal process, including the latest research findings, to help women understand and make decisions about this inevitable event.

If the woman decides to use HT to control her menopausal symptoms, after being thoroughly educated, she will need frequent reassessment. There are no hard-and-fast rules that apply to meeting a woman's individual needs. The nurse can provide realistic expectations of the therapy to reduce the woman's anxiety and concern.

It is also useful to emphasize the value of friends to gain support and share information and resources. Often just talking about emotional difficulties like a death of a parent or problematic relationships helps solve problems. It also shows the woman that her emotional responses are valid.

Healthy lifestyles and stress management techniques are vital to health and longevity, and it is important to keep these on the client's agenda when discussing menopause (Staff of Boston Women's Health Book Collective, 2007).

Evidence-based interventions include lifestyle modifications, risk management therapies, and preventive drug interventions, such as the following:

- Participate actively in maintaining health.
- Exercise regularly.
- Take supplemental calcium and eat appropriately to prevent osteoporosis.
- Stop smoking to prevent lung and heart disease.
- Reduce caffeine and alcohol intake to prevent osteoporosis.
- Monitor blood pressure, lipids, and diabetes (drug therapy management).
- Use low-dose aspirin.
- Reduce dietary intake of fat, cholesterol, and sodium to prevent cardiovascular disease.
- Maintain a healthy weight for body frame.
- Perform breast self-examinations to detect breast lesions.
- Control stress (Dormire & Becker, 2007).

These life approaches may seem low-tech, but they can stave off menopause-related complications such as cardiovascular disease, osteoporosis, and depression. These tips for healthy living work well, but the client needs to be motivated to stick with them.

Key Concepts

- Establishing good health habits and avoiding risky behaviors early in life will prevent chronic conditions later on.
- There are more than 200 symptoms of PMS, and at least two different syndromes have been recognized: PMS and premenstrual dysphoric disorder (PMDD).
- Endometriosis is a condition in which bits of functioning endometrial tissue are located outside their normal site, the uterine cavity.
- Infertility is a widespread problem that has an emotional, social, and economic impact on couples.
- More than half (53%) of all unintended pregnancies occur in women who report using some method of birth control during the month of conception.
- Hormonal methods include oral contraceptives, injectables, implants, vaginal rings, and transdermal patches.
- Recent studies have shown that the extension of active oral contraceptive pills carries the same safety profile as the conventional 28-day regimens.
- Currently there are three IUSs available in the United States: the copper ParaGard-T-380A; Progestasert, a progesterone device; and the levonorgestrel intra-uterine system (LNG-IUS) Mirena, a levonorgestrel-releasing device.
- Sterilization is the most popular method of contraception in the United States and worldwide.
- Menopause, with a dramatic decline in estrogen levels, affects not only the reproductive organs but also other bodily systems.

- Most women with osteoporosis do not know they have the disease until they sustain a fracture, usually of the wrist or hip.
- Half a million women die annually in the United States of cardiovascular diseases, with strokes accounting for about 20% of the deaths.
- Nurses should aim to have a holistic approach to the sexual health of women from menarche through menopause.

REFERENCES

- AAFP (2006). Evidence-based complementary and alternative medicine (CAM): What should physicians know? *Medscape*. Available at: <http://www.medscape.com/viewarticle/549067>
- ACOG Practice Bulletin (2000). Clinical management guidelines for obstetricians-gynecologists, number 15: Premenstrual syndrome. *Obstetrics & Gynecology*, 95, 1–9.
- ACOG (2005). ACOG's Hormone Therapy report. *Obstetrics & Gynecology*, ACOG Task Force, (Supplement to October issue), 1–131.
- Aeby, T. C., & Frattarelli, L. C. (2006). Dysfunctional uterine bleeding. *eMedicine Journal*. Available at: <http://www.emedicine.com/ped/topic628.htm>
- Aeby, T. C., & Hraoka, M. R. (2006). Endometriosis. *eMedicine*. Available at: <http://www.emedicine.com/ped/topic677.htm>
- Alan Guttmacher Institute (2007). Get “in the know”: 20 questions about pregnancy, contraception and abortion. Available at: <http://www.guttmacher.org/in-the-know/index.html>
- Alexander, L. L., LaRosa, J. H., Bader, H., & Garfield, S. (2007). *New dimensions in women's health* (4th ed.). Boston: Jones and Bartlett.
- American Academy of Allergy, Asthma, and Immunology (AAAAI) (2007). Tips to remember: Latex allergy. Available at: <http://www.aaaai.org/patients/publicedmat/tips/latexallergy.stm>
- American Society for Reproductive Medicine (ASRM) (2007). Frequently asked questions about infertility. Available at: <http://www.asrm.org/Patients/faqs.html>
- Anderson, F. D., Gibbons, W., & Portman, D. (2006). Long-term study of an extended-cycle oral contraceptive (Seasonale): A 2-year multicenter open-label extension trial. *American Journal of Obstetrics & Gynecology*, 195(1), 92–96.
- Andoisk, K. M., & Rapkin, A. J. (2007). Contraceptive use in women with premenstrual disorders. *USC Dialogues in Contraception*, 10(4), 4–7.
- Archer, D. F. (2006). Menstrual-cycle-related symptoms: A review of the rationale for continuous use of oral contraceptives. *Contraception*, 74(5), 359–366.
- Arevalo, M. (2007). CycleBeads: Easy, effective natural family planning. Available at: <http://www.cyclebeads.com>
- Bielak, K. M., & Harris, G. S. (2006). Amenorrhea. *eMedicine*. Available at: <http://www.emedicine.com/ped/topic2779.htm>
- Braverman, P. K., & Neinstein, L. S. (2007). Dysmenorrhea and premenstrual syndrome. In L. S. Neinstein (Ed.), *Adolescent health care, a practical guide* (5th ed., pp. 952–965). Philadelphia: Lippincott Williams & Wilkins.
- Brucker, M. C. (2006). Return of the sponge: Will consumers return to a worthy old favorite? *AWHONN Lifelines*, 10(1), 74–76.
- Campagne, D. M., & Campagne, G. (2007). The premenstrual syndrome revisited. *European Journal of Obstetrics & Reproductive Biology*, 130(1), 4–17.
- Campbell, S. (2006). Bioidentical hormones: Achieving the perfect fit. *Advance for Nurse Practitioners*, 14(2), 25–30.
- Canning, S., Waterman, M., & Dye, L. (2006). Dietary supplements and herbal remedies for premenstrual syndrome (PMS): A systematic review of the evidence for their efficacy. *Journal of Reproductive & Infant Psychology*, 24(4), 363–378.
- Centers for Disease Control and Prevention (CDC) (2006). Contraceptive use. National Center for Health Statistics. Available at: <http://www.cdc.gov/women/natstat/reprhth.htm#contraception>
- Chedraul, P., Hidalgo, L., Chavez, D., Moroch, N., Alvarado, M., & Huc, A. (2007). Menopausal symptoms and associated risk factors among postmenopausal women screened for the metabolic syndrome. *Archives of Gynecology & Obstetrics*, 275(3), 161–168.
- Cheng, L., Gulmezoglu, A. M., Van Oel, C. J., Piaggio, G., Ezcurra, E., & Van Look, P. F. A. (2006). Interventions for emergency contraception. *Cochrane Library*: CD001324, 2009357452.
- Clayton, A. H. (2008). Symptoms related to the menstrual cycle: Diagnosis, prevalence, and treatment. *Journal of Psychiatric Practice*, 14(1), 13–21.
- Courtney, K. (2006). The contraceptive patch: Latest developments. *AWHONN Lifelines*, 10(3), 250–253.
- Covington, S., & Burns, L. H. (2006). *Infertility counseling: A comprehensive handbook for clinicians* (2nd ed.). Cambridge, UK: Cambridge University Press.
- Curlin, F. A., Lawrence, R. E., Chin, M. H., & Lantos, J. D. (2007). Religion, conscience, and controversial clinical practice. *New England Journal of Medicine*, 356(6), 593–600.
- Dassow, P., & Bennett, J. M. (2006). Vasectomy: An update. *American Family Physician*, 74(12), 2069–2074.
- DeMasters, J. (2004). Male infertility. *Advance for Nurses*, 6(1), 19–25.
- DeSutter, P. (2006). Rational diagnosis and treatment in infertility. *Best Practice & Research: Clinical Obstetrics & Gynecology*, 20(5), 647–664.
- Dirubbo, N. E. (2006). Counsel your patients about contraceptive options. *Nurse Practitioner*, 31(4), 40–44.
- Dodds, N., & Sinert, R. (2006). Dysfunctional uterine bleeding. *eMedicine*. Available at: <http://www.emedicine.com/emerg/topic155.htm>
- Dormire, S., & Becker, H. (2007). Menopause health decision support for women with physical disabilities. *JOGNN*, 36(1), 97–104.
- Doty, E., & Attaran, M. (2006). Managing primary dysmenorrhea. *Journal of Pediatric & Adolescent Gynecology*, 19(5), 341–344.
- Edelman, A. B., Gallo, M. F., Jensen, J. T., Nichols, M. D., Schulz, K. F., & Grimes, D. A. (2006). Continuous or extended cycle versus cyclic use of combined oral contraceptives. *Cochrane Library*: CD004695
- Edmundson, L. D., & Eroglu, M. (2006) Dysmenorrhea. *eMedicine*. Available at: <http://www.emedicine.com/emerg/topic156.htm>
- Female Contraception (2006). *Contraception: Female, annual report*. ADAM. Available at: <http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=20517070&site=ehost-live>
- Fiorelli, C. T., & Weeks, B. (2007). Untangling the complexities of male infertility. *Nursing2007*, 37(1), 24–26.
- French, R., Vliet, H., Cowan, F., Mansour, D., Morris, S., Hughes, D., Robinson, A., Proctor, T., Summerbell, C., Logan, S., Helmerhorst, F., & Guillebaud, J. (2006). Hormonally impregnated intrauterine systems (IUSs) versus other forms. *Cochrane Library*. CD001776: 2009357603.
- Futerman, L. A., & Rapkin, A. J. (2006). Diagnosis of premenstrual disorders. *Journal of Reproductive Medicine*, 51(4), 349–358.
- Gallo, M. F., Grimes, D. A., Lopez, L. M., & Schultz, K. F. (2006). Nonlatex versus latex condoms for contraception. *Cochrane Library*. Available at: www.cinahl.com/cgi-bin/refsrv/jid=3053&accno=2009358379
- Gallo, M., Grimes, D., & Schultz, K. (2006). Cervical cap versus diaphragm for contraception. *Cochrane Library*. Available at: <http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=2009358282&site=ehost-live>
- Giulio, G. D., & Reissing, E. D. (2006). Premenstrual dysphoric disorder: Prevalence, diagnostic considerations, and controversies. *Journal of Psychosomatic Obstetrics & Gynecology*, 27(4), 201–210.
- Grady, D. (2006). Management of menopausal symptoms. *New England Journal of Medicine*, 355(22), 2338–2347.
- Grainger, D. A., Frazier, L. M., & Rowland, C. A. (2006) Preconception care and treatment with assisted reproductive technologies. *Maternal & Child Health*, (Supplement 10), 161–164.
- Graziottin, A. (2006). A review of transdermal hormone contraception: Focus on the ethinyl estradiol/norelgestromin contraceptive patch. *Treatments in Endocrinology*, 5(6), 359–365.
- Haas, E. (2007). Easing menopause symptoms naturally. *Share Guide*, 89, 29–78.
- Hackley, B., Kriebs, J. M., & Rousseau, M. E. (2007). *Primary care of women: A guide for midwives and women's health providers*. Sudbury, MA: Jones and Bartlett Publishers.
- Hansberger, J. (2007). Osteoporosis: Review of disease, diagnosis, and treatments for the advanced practice nurse. *Journal of Advanced Nursing Practice*, 8(1), 5–6.

- Harel, Z. (2006). Dysmenorrhea in adolescents and young adults. *Journal of Pediatric & Adolescent Gynecology*, 19(6), 363–371.
- Hatcher, R. A., et al. (2004). *Contraceptive technology* (18th ed.). New York: Ardent Media, Inc.
- Hearton, L. (2006). Long-acting methods of reversible contraception. *Primary Health Care*, 16(4), 21–22.
- Hompes, P. G., & Mijatovic, V. (2007). Endometriosis: The way forward. *Gynecological Endocrinology*, 23(1), 5–12.
- Hsiao, M., & Liu, C. (2007). Unusual manifestations of premenstrual syndrome. *Psychiatry & Clinical Neurosciences*, 61(1), 120–123.
- Htay, T. T., & Aung, K. (2006). Premenstrual dysphoric disorder. *Emedicine*. Available at: <http://www.emedicine.com/med/topic3357.htm>
- Huntzinger, A. (2006). ACOG reports on compounded bioidentical hormones. *American Family Physician*, 73(12), 2242–2245.
- Jenkins, G., & Jenkins, J. (2006). Issues relating to infertility. *Practice Nurse*, 32(4), 14–22.
- Kelly-Weeder, S., & O'Conner, A. (2006). Modifiable risk factors for impaired fertility in women: What nurse practitioners need to know. *Journal of the American Academy of Nurse Practitioners*, 18(6), 268–276.
- Kessenich, C. R. (2007). Inevitable menopause. *Nursing Spectrum*. Available at: <http://www.nurse.com/ce/course.html?CCID=3183ce232.htm>
- Krantz, C. (2007a). Amenorrhea. In R. E. Rakel (Ed.), *Conn's current therapy 2007*. Philadelphia: Elsevier W. B. Saunders.
- Krantz, C. (2007b). Menstrual cycle. In R. E. Rakel (Ed.), *Conn's current therapy 2007*. Philadelphia: Elsevier W. B. Saunders.
- Lenahan, G. P. (2004). Latex allergy: Separating fact from fiction. *Travel Nursing*, pp. 12–17.
- Lethaby, A., Cooke, I., & Rees, M. (2006). Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. *Cochrane Database Systematic Review* (4), CD002126.
- Lever, K. A. (2005). Emergency contraception. *AWHONN Lifelines*, 9(3), 218–225.
- Manson, J. E. (2006). Perimenopause, hormones, and midlife health. *Harvard Women's Health Watch*, 14(3), 1–3.
- Master-Hunter, T., & Heiman, D. L. (2006). Amenorrhea: Evaluation and treatment. *American Family Physician*, 73(8), 1374–1382.
- McKinney, L. N. (2007). Low libido in postmenopausal women. *Advance for Nurse Practitioners*, 15(1), 28–36.
- McNally, D. N., Kenny, A. M., & Smith, J. A. (2007). Adherence of academic geriatric practitioners to osteoporosis screening guidelines. *Osteoporosis International*, 18(2), 177–183.
- Mishell, D. R., Guillebaud, J., Westoff, C., Nelson, A. L., Kaunitz, A. M., Trussell, J., & Davis, A. J. (2007). Combined hormonal contraceptive traits: Variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. *Contraception*, 75(1), 4–10.
- Moreno, M. A., & Giesel, A. E. (2006). Premenstrual syndrome. *Emedicine*. Available at: <http://www.emedicine.com/ped/topic1890.htm>
- Murphy, P. A., Morgan, K., & Likis, F. E. (2006). Contraception. In K. D. Schuiling & F. E. Likis (Eds.), *Women's gynecologic health* (pp. 169–228). Sudbury, MA: Jones and Bartlett Publishers.
- Nasir, L. S. (2007). Dysmenorrhea. In R. E. Rakel & E. T. Bope (Eds.), *Conn's current therapy 2007* (pp. 1238–1240). Philadelphia: Saunders.
- National Institute of Child Health and Human Development (NICHD) (2006). Endometriosis. NICHD Information Resource Center, NIH Pub. No. 02-2413. Available at: <http://www.nichd.nih.gov/health/topics/Endometriosis.cfm>
- National Osteoporosis Foundation (NOF) (2007). Steps to prevent osteoporosis. Available at: <http://www.nof.org/prevention/index.htm>
- Nelson, L. M., & Bakalov, V. (2006). Amenorrhea. *eMedicine*. Available at: <http://www.emedicine.com/med/topic117.htm>
- Newton, K. M., Reed, S. D., LaCroix, A. Z., Grothaus, L. C., Ehrlich, K., & Guiltinan, J. (2006). Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo. A randomized trial. *Annals of Internal Medicine*, 145, 869–879.
- North American Menopause Society (NAMS) (2004). Recommendations for estrogen and progesterone use in peri-menopausal and post-menopausal women. *Menopause*, 11(6), 589–600.
- OSHA (2006). Latex allergy. U.S. Department of Labor, Occupational Safety & Health Administration. Available at: <http://www.osha.gov/SLTC/latexallergy>
- Pagana, K. D., & Pagana, T. J. (2007). *Mosby's diagnostic and laboratory test reference* (8th ed.). Philadelphia: Elsevier Mosby.
- Pavlovich-Danis, S. J. (2007). Cyclic upheaval: Premenstrual syndrome and premenstrual dysphoric disorder. *Nursing Spectrum*. Available at: <http://www.nurse.com/ce/course.html?CCID=3297>
- Planned Parenthood (2007). Facts about birth control. Available at: <http://www.plannedparenthood.org/bc/bcfacts4.html>
- Quallich, S. (2006). Examining male infertility. *Urologic Nursing*, 26(4), 277–288.
- Rackow, B. W., & Arici, A. (2007). Dysfunctional uterine bleeding. In R. E. Rakel & E. T. Bope (Eds.), *Conn's current therapy 2007* (pp. 1230–1232). Philadelphia: Saunders.
- Ravin, C. R. (2006). Considering contraception: What practitioners are saying. *AWHONN Lifelines*, 10(2), 122–128.
- Redshaw, M., Hockley, C., & Davidson, L. L. (2007). A qualitative study of the experience of treatment for infertility among women who successfully become pregnant. *Human Reproduction*, 22(1), 295–304.
- Robinson, K. (2005). Depo-Provera: New concerns—same issues? *AWHONN Lifelines*, 9(3), 214–217.
- Roederer, M. W., Blackwell, J., & Blenning, C. (2006). Risks and benefits of combination contraceptives. *American Family Physician*, 74(11), 1915–1916.
- Rosano, G. M., Vitale, C., Marazzi, G., Voltazzi, G., & Volterrani, M. (2007). Menopause and cardiovascular disease: The evidence. *Climacteric* (Supplement 1, 10), 19–24.
- Rubin, R. (2007). A herbal menopause therapy: Get a closer look. *USA Today*, Jan. 11, 2007, p. 7.
- Samra, O. M., & Wood, E. (2006). Contraception. *Emedicine*. Available at: <http://www.emedicine.com/med/topic3211.htm>
- Saul, T., & Dave, A. K. (2006). Endometriosis. *Emedicine*. Available at: <http://www.emedicine.com/EMERG/topic165.htm>
- Schenker, J. G. (2005). Assisted reproductive practice: Religious perspectives. *Reproductive BioMedicine*, 10(3), 310–319.
- Schuiling, K. D., & Likis, F. E. (2006). *Women's gynecologic health*. Sudbury, MA: Jones and Bartlett Publishers.
- Seppa, N. (2007). Putting the kibosh on black cohosh. *Science News*, 171(2), 29–30.
- Shelby, K., & O'Hair, K. (2007). Hormone replacement therapy: What we know now. *Nursing Spectrum*. Available at: <http://www.nurse.com/ce/course.html?CCID=2325&PageNum=3&Begin=11545>
- Sinai, I., Arevalo, M., & Jennings, V. (2006). Fertility awareness-based methods of family planning: Predictors of correct use. *International Family Planning Perspectives*, 32(2), 94–100.
- Skidmore-Roth, L. (2007). *Mosby's drug guide for nurses* (7th ed.). St. Louis, MO: Elsevier Mosby.
- Smith, R. P. (2006). Finding the best approach to dysmenorrhea. *Contemporary OB/GYN*, 51(11), 54–62.
- Speroff, L., & Fritz, M. A. (2005). *Clinical gynecologic endocrinology and fertility* (7th ed.). Philadelphia: Lippincott Williams & Wilkins.
- Staff of the Boston Women's Health Book Collective (2007). *Our bodies, ourselves: Menopause*. New York: Simon & Schuster Trade.
- Stewart, F. H., Kaunitz, A. M., LaGuardia, K. D., Karvois, D. L., Fisher, A. C., & Friedman, A. J. (2006). Extended use of transdermal norelgestromin/ethinyl estradiol: A randomized trial. *Obstetrics & Gynecology*, 105(6), 1389–1396.
- Swica, Y., & Westhoff, C. (2006). Update on new contraceptive choices. *Journal of Clinical Outcomes Management*, 13(8), 447–455.
- Taylor, D. (2005). Perimenstrual symptoms and syndromes: Guidelines for symptom management and self-care. *Advanced Studies in Medicine*, 5(5), 228–241.
- Tolaymat, L. L., & Kaunitz, A. M. (2007). Contraceptive methods. In R. E. Rakel & E. T. Bope (Eds.), *Conn's current therapy 2007* (pp. 882–885). Philadelphia: Saunders.
- Torpy, J. M. (2007). Polycystic ovary syndrome. *JAMA*, 297(5), 554–557.
- Trussell, J. (2004). Contraceptive efficacy. In R. Hatcher, et al. (Eds.), *Contraceptive technology* (18th rev. ed.). New York: Ardent Media, Inc.
- UNFPA (2007). *The state of the world population 2006 report*. Available at: <http://www.unfpa.org/swp/swpmain.htm>
- U.S. Bureau of the Census (2006). *National population estimates—characteristics*. Available at: <http://eire.census.gov/popest/data/national/tables/asro/NA-EST2002-ASRO-01.php>

- U.S. Food & Drug Administration (FDA) (2006). FDA approves over-the-counter access for Plan B for women 18 and older; prescription remains required for those 17 and younger. *FDA News* (August 24, 2006). Available at: www.fda.gov/bbs/topics/NEWS/2006/New01436.html
- Valle, R. F. (2006). Combination of tubal sterilization and endometrial ablation is safe and effective. *Fertility and Sterility*, 86(1), 152–158.
- World Health Organization (WHO) (2007). Infertility in developing countries. *Reproductive Health*. Available at: <http://www.who.int/reproductive-health/infertility/index.htm>
- Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. *JAMA*, 288(3), 321–333.
- Wysocki, S. (2007). Clinical rationale for continuous oral contraception. *American Journal for Nurse Practitioners*, 11(3), 57–67.
- Youngkin, E. Q., & Davis, M. S. (2004). *Women's health: A primary care clinical guide* (3rd ed.). New Jersey: Prentice Hall.
- American Society for Reproductive Medicine: (205) 978-5000, <http://www.asrm.org>
- Centers for Disease Control and Prevention: (202) 329-1819, <http://www.cdc.gov>
- Consortium for Emergency Contraceptive: <http://www.cecinfo.org>
- Center for Reproductive Rights: <http://www.crlp.org>
- Emergency Contraception Hotline: (888) 668-2528, <http://www.not-2-late.com>
- Endometriosis Association: (414) 355-2200, <http://www.ovf.com/endohtml.html>
- FDA's Office of Women's Health: <http://www.fda.gov/womens>
- Hormone Foundation: (800) 467-6663, <http://hormone.org>
- International Counsel on Infertility Information Dissemination: (703) 379-9178, <http://www.inciid.org>
- National Institute of Mental Health: (301) 443-4513, <http://www.nimh.nih.gov>
- National Women's Health Resource Center: (877) 986-9472, <http://www.healthywomen.org>
- National Women's Information Center (NWHIC): (800) 994-9662, <http://www.4women.gov>
- North American Menopause Society: <http://www.menopause.org>
- Planned Parenthood Federation of America, Inc.: (800) 669-0156, <http://www.plannedparenthood.org>
- Premenstrual Institute: (248) 624-3366, <http://www.pmsinst.com>
- Resolve, The National Infertility Association: (617) 623-0744, <http://www.resolve.org>

WEBSITES

- American College of Obstetricians and Gynecologists (ACOG): (202) 863-2518, <http://www.acog.org>
- American Psychiatric Association: (202) 682-6000, <http://psych.org>

CHAPTER WORKSHEET

MULTIPLE CHOICE QUESTIONS

1. A couple is considered infertile after how many months of trying to conceive?
 - a. 6 months
 - b. 12 months
 - c. 18 months
 - d. 24 months
2. A couple reports that their condom broke while they were having sexual intercourse last night. What would you advise to prevent pregnancy?
 - a. Inject a spermicidal agent into her vagina immediately.
 - b. Obtain emergency contraceptives and take them immediately.
 - c. Douche with a solution of vinegar and hot water tonight.
 - d. Take a strong laxative now and again at bedtime.
3. Which of the following combination contraceptives has been approved for extended continuous use?
 - a. Seasonale
 - b. NuvaRing
 - c. Ortho Evra
 - d. Mirena
4. Which of the following measures helps prevent osteoporosis?
 - a. Iron supplementation
 - b. Sleeping 8 hours nightly
 - c. Eating lean meats only
 - d. Walking 3 miles daily
5. Which of the following activities will increase a woman's risk of cardiovascular disease if she is taking oral contraceptives?
 - a. Eating a high-fiber diet
 - b. Smoking cigarettes
 - c. Taking daily multivitamins
 - d. Drinking alcohol
6. Hormone therapy taken by menopausal women reduces:
 - a. Weight gain
 - b. Bone density
 - c. Hot flashes
 - d. Heart disease
7. Throughout life, a woman's most proactive activity to promote her health would be to engage in:
 - a. Consistent exercise
 - b. Socialization with friends
 - c. Quality quiet time with herself
 - d. Consuming water
8. What comment by a woman would indicate that a diaphragm is not the best contraceptive device for her?
 - a. "My husband says it is my job to keep from getting pregnant."
 - b. "I have a hard time remembering to take my vitamins daily."
 - c. "Hormones cause cancer and I don't want to take them."
 - d. "I am not comfortable touching myself down there."

CRITICAL THINKING EXERCISE

1. Ms. London, 25, comes to your family planning clinic requesting to have an intrauterine system (IUS) inserted because "birth control pills give you cancer." In reviewing her history, you note she has been into the STI clinic three times in the past year with vaginal infections and was hospitalized for pelvic inflammatory disease (PID) last month. When you question her about her sexual history, she reports having sex with multiple partners and not always using protection.
 - a. Is an IUS the most appropriate method for her? Why or why not?
 - b. What myths/misperceptions will you address in your counseling session?
 - c. Outline the safer sex discussion you plan to have with her.

STUDY ACTIVITIES

1. Develop a teaching plan for an adolescent with premenstrual syndrome and dysmenorrhea.
2. Arrange to shadow a nurse working in family planning for the morning. What questions does the nurse ask to ascertain the kind of family planning method that is right for each woman? What teaching goes along with each method? What follow-up care is needed? Share your findings with your classmates during a clinical conference.
3. Surf the Internet and locate three resources for infertile couples to consult that provide support and resources.
4. Sterilization is the most prevalent method of contraception used by married couples in the United States. Contact a local urologist and gynecologist to learn about the procedure involved and the cost of a male and female sterilization. Which procedure poses less risk to the person and costs less?
5. Take a field trip to a local drugstore to check out the variety and costs of male and female condoms. How many different brands did you find? What was the range of costs?
6. Noncontraceptive benefits of combined oral contraceptives include which of the following? Select all that apply.
 - a. Protection against ovarian cancer
 - b. Protection against endometrial cancer
 - c. Protection against breast cancer
 - d. Reduction in incidence of ectopic pregnancy
 - e. Prevention of functional ovarian cysts
 - f. Reduction in deep venous thrombosis
 - g. Reduction in the risk of colorectal cancer